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Naturally occurring compounds and lifestyle modifications as combination and monotherapy are increasingly used for dyslipidemia. Specficially, phytosterols and fatty acids have
demonstrated an ability to modulate cholesterol and triglyceride metabolism in different fashions.
In two separate studies, the lipid-lowering effects of black raspberry seed oil and three different
phytosterol stearates were examined in order to elucidate the effects of these dietary components
and the factors influencing their therapeutic actions.
The first study examined high cholesterol diets supplemented with crude and refined
black raspberry seed oils, coconut oil or soybean oil. The crude and refined raspberry seed oil
(RSO) treatments significantly altered lipid metabolism, lowering plasma and liver triglycerides
while increasing cholesterol ester liver accumulation. Despite the typical reduction of phytosterol
content in oils upon processing, both the composition and metabolic effects of the oils did not
differ with the exception of increase bile acid excretion in the refined oil.
The second study investigated three phytosterol stearates varying in their phytosterol
composition: sitosterol, stigmasterol, or sitostanol. All diets were high in cholesterol and fat to
induce dyslipidemia. The phytosterol stearate treatments did not significantly lower plasma
cholesterol levels; however, free cholesterol concentrations in the liver were beneficially reduced

by both the stanol stearate and sitosterol stearate dietary treatments. Fecal neutral sterol excretion
was elevated in the stanol stearate and sitosterol stearate groups versus the cornstarch control, an
effect absent in the stigmasterol stearate treatment, indicating that sitosterol stearate may be more
effective than stigmasterol stearate at inducing neutral sterol loss via fecal excretion during this
study at a 2.5% (g/g) dose.
In summary, both studies demonstrated beneficial but conservative impacts upon
cholesterol metabolism by the specified treatments, indicating that RSOs may be a beneficial
therapy and that phytosterol stearates do not dramatically differ in their effects upon cholesterol
metabolism at a 2.5% dose.
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Introduction
Cardiovascular diseases (CVD) are collectively responsible for 29% of global deaths,
according to data from the World Health Organization (W.H.O. September 2009). Because of the
prevalence of these diseases and the ability to modify susceptibility to disease progression via
lifestyle changes (diet and exercise) and drug therapies, considerable research has been devoted to
one of the primary risk factors for the beginning of atherosclerosis and the plaque buildup that
often progresses to cardiovascular diseases: plasma low-density lipoprotein concentrations
(Lloyd-Jones, Adams et al.). While drug therapy involving statins, ezetimibe, or fenofibrates are
effective in modulating and correcting dyslipidemia, other means are required for both low-risk
individuals and patients experiencing adverse effects of drugs. Specifically, phytosterols have
been historically utilized as an effective nutraceutical lipid-lowering therapy to aid in the
prevention of CVD.
The purpose of this research was to examine the lipid-lowering effects of black raspberry
seed oil and phytosterol stearates in two separate studies in order to further define the parameters
for nutraceutical applications of these food products and gain a deeper understanding of how
these therapies may exert their effects.
The first study consisted of examining the lipid-modulating effects of crude and refined
black raspberry seed oil when added to high cholesterol and high fat diets in male Syrian
hamsters. The raspberry seed oil (RSO) study included both a positive soybean oil control
(known to beneficially decrease plasma cholesterol levels) and a negative coconut oil control
(known to detrimentally elevate plasma cholesterol levels)(Jackson et al 1984). The two RSO
diets differed in their extent of processing: the crude oil was not processed but the refined oil was
refined and deodorized. Typically, the procedure reduces the phytosterol concentration of the oil
by about one half.(Johansson and Hoffmann 1979, Mounts 1981) By design, the study sought to
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determine whether the extent of oil processing affects the lipid-lowering capabilities of black
raspberry seed oil, either due to different phytosterols concentrations or other factors.
The second study examined three different phytosterol stearates in comparison to a
coconut oil negative control in order to determine whether there are distinct advantageous affects
that distinguish the efficacy of different phytosterol stearates based upon the phytosterol
component. Examining phytosterol esters in current common use, the study investigated their
comparative ability to decrease plasma low-density lipoprotein cholesterol concentrations and
other lipid metabolic parameters. Specifically, the study was designed to determine the effect of
the sterol moiety attached to the fatty acid stearate in order to both understand the mechanism of
action more comprehensively and to determine the most effective therapeutic option. The
phytosterol stearates investigated were sitosterol stearate, stigmasterol stearate, and
stigmastanol/sitostanol stearate (the collective dehydrogenation product of both sitosterol and
stigmasterol, thus the compound will be referred to as stanol stearate in this text; Figure 1). By
designing the study to examine the effects of sitosterol, stigmasterol, and the collective stanol
moieties after controlling for the esterified stearate, insight into the effect of phytosterol structure
was hoped to be achieved, specifically in regards to double-bond placement: (1) within the steroid
ring (sitosterol); (2) the side-chain and the ring (stigmasterol); (3) or no double bonds (stanol).
In our investigations into the effect of black raspberry seed oil and phytosterol esters on
LDL metabolism and plasma levels, we used the Charles River outbred Syrian hamster as our
animal model because of the similarity to humans in response to a high fat, high cholesterol
diet.(Dorfman et al 2005) When hamsters are challenged with a high fat, high cholesterol diet,
they develop atherosclerosis and plaques that resemble those formed in humans.(Dorfman et al
2003, Mawatari et al 2004, Nistor et al 1987, Otto et al 1995) Furthermore, hamsters are a good
model for investigating the progression of atherosclerosis not only because of similar plaque
histology but because of similar cholesterol transport distribution. Cholesterol plasma transport
mirrors the human condition more closely than other rodents, as hamsters carry a significant
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portion of plasma cholesterol in low-density lipoproteins when placed on atherogenic diets (high
fat, high cholesterol).(Lock et al 2005) When hamsters are placed on a high cholesterol diet (at
least 0.1% g/g), low-density lipoprotein cholesterol levels become elevated, an effect that is
sensitive to saturated fat intake in a similar manner as in humans, indicating appropriateness as a
comparative atherosclerotic model.(Gajda et al 2007)
Although the majority of cholesterol synthesis occurs extrahepatically in all tissues, the
liver contributes the most of any single tissue to the cholesterol synthetic pool; and thus takes a
primary focus in cholesterol metabolism management.(Dietschy et al 1993, Spady and Dietschy
1983) Estimates of whole body cholesterol synthesis and metabolism place the same level of
synthetic and regulatory importance on the liver in both humans and hamsters, indicating another
shared similarity and further justifying the use of hamsters as a model of atherosclerosis.
Hamsters fed high saturated fat and high cholesterol diets begin developing aortic atherosclerotic
lesions similar in structure and modeling to atherosclerosis in humans after only four weeks of
dietary treatment. Because animals (and humans) tightly regulate cholesterol metabolism, it takes
a significant amount of time to induce significant changes via dietary interventions; thus, we have
designed the length of our studies to be four weeks in order to ensure lipid metabolism
homeostasis.(Pien et al 2002)

Clarification of terms. The term ―phytosterol‖ within this publication is used to refer to plant
sterols and plant stanols collectively, whereas the terms ―plant sterol‖ and ―plant stanol‖ are used
to refer to each specific species. Even though sitostanol and stigmastanol are equivalent
structurally, the term ―sitostanol‖ will be used to refer to the compound, which can be synthesized
via hydrogenation of either sitosterol or stigmasterol.
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Literature Review
I. Cardiovascular Disease and Atherogenesis

Because cardiovascular diseases (CVD) are globally the leading cause of death, research
has investigated the etiology, pathology, and clinical treatment of the two major types of CVD:
strokes and coronary heart disease (CHD)(NCEP 2002). Both major cardiovascular disease
categories are associated with several risk factors including smoking, lack of physical activity,
high blood pressure, and dyslipidemia (Lloyd-Jones et al 2010) Subsequently, research has
investigated substances and therapeutic options that lower LDL cholesterol levels and thereby
decrease CVD risk.(NCEP 2002) Atherosclerosis, a major pathological etiology of CVD, is the
narrowing of the arteries of the vascular system due to cholesterol deposition, foam cell
formation, and subsequently the initiation of fatty streaks. In response to the damage to the
endothelial cells of the vascular tissue, clotting factors stimulate the formation of a thrombus to
halt the degradation of the endothelial layer of the vessel. However, with increasing foam cell
accumulation and inflammatory oxidation, the thrombus eventually ruptures, potentially blocking
arteries and halting blood flow to organs and tissues.
The importance of Low-Density Lipoprotein (LDL) cholesterol in the disease process is
paramount and has received much attention, as the oxidation or modification of LDL results in
the migration of LDL into the intima of the artery and the genesis of an atherosclerotic
plaque.(Matsuura et al 2008) Oxidized LDL is more rapidly taken up by macrophages in intima
than native unmodified LDL, resulting in cholesterol accumulation in the cells, the formation of
foam cells, and atherogenesis.(Matsuura et al 2008) Subsequently, high circulating LDL
cholesterol concentrations in the bloodstream are a known risk factor for atherosclerosis and
CHD.(Kiechl and Willeit 1999) Historically, this led to the recommendation of decreasing dietary
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cholesterol intake in order to decrease circulating cholesterol levels. However, recent research has
indicated that dietary cholesterol does not significantly contribute to atherosclerosis or the risk of
CHD in the general population, as it increases both the LDL fraction of cholesterol and the HDL
fraction, the anti-atherogenic fraction.(McNamara 2000) In fact, research has demonstrated that
the fatty acid composition of the diet is a more important lifestyle modulator of LDL cholesterol
levels, as high levels of saturated fatty acids and trans fatty acids intakes have been shown to
result in elevated plasma LDL cholesterol concentrations (Oh et al 2005). Because of decreased
risk of CHD and atherosclerosis associated with low LDL cholesterol concentrations, the
National Cholesterol Education Program has recently designated the optimum plasma LDL target
concentration to be <100 mg/dl (NCEP 2001).
Current therapeutic preventative action focuses on lowering the LDL cholesterol
concentration in order to decrease atherosclerotic and CHD relative risk. Pharmalogically, statins
or 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase) inhibitors are used to
decrease the synthesis of cholesterol within the body by inhibiting the activity of HMG-CoA
reductase, the rate-limiting enzyme in cholesterol synthesis. However, recent research has
demonstrated that statins are not as safe as once believed, resulting in adverse events in 29.5% of
patients in the case of simvastatin.(Kastelein et al 2008)
With high rates of side effects, statins are not the best option for everyone due to
potential hepatotoxicity and other tissue damage. Even moderately dosed statin therapy is not the
most appropriate choice for reducing CHD risk in the majority of the population because of the
increased occurrence of adverse events, including liver function abnormalities and elevations in
creatine kinase.(Silva et al 2007) Statins were shown to elevate serum alanine aminotransferase
and aspartate aminotransferase levels, indicating a hepatotoxic response to treatment.(Kashani et
al 2006) Furthermore, while statins are potent drugs for LDL concentration reduction, the
consumption of phytosterol enriched margarines by statin users resulted in a 10% reduction of
LDL cholesterol, whereas doubling the statin dose only produced an additional decrease in LDL
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cholesterol of 3-7%.(De Jong et al 2008b) Thus, other treatment options must be considered in
combination with statin treatments and as stand-alone preventative measures.

II. Effect of Phytosterols on Cholesterol Metabolism

While there are many compounds currently undergoing research for their plasma LDL
cholesterol-lowering effects, plant sterols and stanols are among the most potent. Phytosterols
decrease cholesterol absorption up to 40% and have been shown to effectively lower plasma total
cholesterol, LDL cholesterol, and apo-B (the lipoprotein required for LDL formation) at a dosage
of 1.8 g/day regardless of the initial plasma cholesterol condition of the patient.(Miettinen and
Gylling 2004, Ntanios et al 2002) While naturally occurring plant stanols contribute only 5-10%
to total phytosterol abundance observed in nature (Carr et al 2006), both free and esterified plant
sterols and stanols lower LDL cholesterol levels in hypercholesterolemic, mildly
hypercholesterolemic, and normal individuals.(Ntanios et al 2002)
In a typical modern diet, phytosterol intake is roughly 160-360 mg/day; thus, the dosage
recommended simply recommends the increase of a nutritive substance already found in our food
supply.(Morton et al 1995) The currently proposed mechanism responsible for the majority of
phytosterol LDL-lowering relies upon the displacement of cholesterol from micelles, resulting in
a reduction in the amount of cholesterol hydrolyzed and available for absorption.(Awika and
Rooney 2004) The reduction in cholesterol absorption (both of dietary and biliary cholesterol)
forces the body to increase cholesterol synthesis and LDL cholesterol uptake into the liver,
clearing the blood of LDL cholesterol.(Carr et al 2006) However, in order to maximize practical
applications of administration, plant sterols can be esterified with long chain fatty acids to
increase their solubility in oil from 2% to 20% without impairing their ability to decrease
cholesterol absorption.(Jandacek et al 1977, Mattson et al 1977) In a long term study over eightyfive weeks, Plant sterol and stanol ester consumption reduced LDL cholesterol 8.7% and 13.1%
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respectively (De Jong et al 2008b). After one week, plant sterol consumption lowers serum
cholesterol by 16%, cholesterol absorption by 40%, and fecal output of cholesterol by 36%; thus,
plant sterol/stanols and phytosterol esters reduce plasma LDL cholesterol concentrations and
CHD risk.(Gould et al 2007)

III. Clinical Aspects of Phytosterol Therapy

Because there is strong evidence of an association between elevated low-density
lipoprotein cholesterol (LDL-C) levels and cardiovascular disease, LDL-C lowering therapies
have received much attention, especially because they have demonstrated an ability to reduce
relative disease risk even in individuals with average serum levels.(Downs et al 1998, Martin et al
1986, Stamler et al 1986) Furthermore, lowering serum LDL-C and increasing high-density
lipoprotein cholesterol (HDL-C) has been shown to lead to a regression in atherosclerotic lesion
progression.(Nissen et al 2006) Because common drug therapies, such as statins and fibrates, do
induce adverse effects, much interest has been generated in using alternative LDL-C lowering
strategies.(Florentin et al 2008, Kiortsis et al 2007) Adverse effects of statins have been shown to
be dose-dependent, indicating any combination treatment that lowers the drug dose via
substitution with phytosterol supplementation would be beneficial.(Golomb and Evans 2008)
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Natural plant sterol intake

Plant sterols, stanols, and their collective esters are therapeutically used to lower LDL-C
both as a monotherapy and in combination with drugs in both normocholesterolemic and
hypercholesterolemic individuals (Ntanios et al 2002, Quilez et al 2003a). In a Northern Swedish
population, investigators demonstrated an inverse correlation between plant sterol intake and
serum LDL-C levels, suggesting the possibility that phytosterols may reduce serum cholesterol
concentrations even at normal dietary intake levels (Klingberg et al 2008). Ostlund et al. (2003)
demonstrated that human subjects fed phytosterol-free wheat germ oil incorporated into a
breakfast muffin in place of wheat germ oil naturally high in phytosterols increased serum
radiolabeled cholesterol enrichment by 42.8%, indicating that naturally occurring levels of
phytosterols may attenuate cholesterol absorption even after a single dose (Ostlund et al 2003).
This response was also demonstrated utilizing corn oils (Ostlund et al 2002b).
However, the reduction of cholesterol absorption does not necessitate that a significant
decrease in LDL-C is obtained. While a phytosterol-deficient diet supplemented with 400 mg/d of
phytosterols did not quite produce a statistical reduction of LDL-C (p=0.077), the natural
phytosterol intake level decreased cholesterol absorption and increased both total fecal
cholesterol and biliary cholesterol excretion (Racette et al 2009). Viewed altogether, a baseline
dietary intake of phytosterols has a significant positive effect upon cholesterol metabolism
(Racette et al 2009). Despite the possible importance of dietary phytosterols in cholesterol
metabolism, supplemental doses of phytosterols are required to achieve maximal reductions of
elevated LDL-C concentrations in many individuals.
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Phytosterol Supplementation Efficacy and Dose

While natural phytosterol intakes may have hypocholesterolemic effects, a higher dose of
phytosterols via supplementation dramatically and positively influences cholesterol metabolism,
consistently lowering LDL-C about 10%.(Katan et al 2003) Wu et al. published a meta-analysis
of phytosterol supplementation, concluding that administration lowers serum total cholesterol
(TC), LDL-C, and triglycerides.(Wu 2009) Upon evaluation of the 20 publications analyzed (Wu
2009), only one demonstrated a significant triglyceride-lowering effect (Maki et al 2001). Most
published meta-analyses are in agreement that phytosterols do not affect either serum
triglycerides or high-density lipoprotein cholesterol (HDL-C).(Katan et al 2003, Law 2000,
Moruisi et al 2006) The meta-analysis of Katan et al. (2003) acknowledged the phytosterols
lowered serum triglycerides in a few studies but asserted that the effect is sporadic and not
supported by the general body of literature.(Katan et al 2003)
The main action of phytosterols is to lower LDL-C and subsequently total cholesterol.
While 0.83, 1.6, and 3.24 grams per day (g/d) did not differ significantly in LDL-C lowering
capacity, most meta-analyses conclude that phytosterols lower LDL-C dose-dependently up to 2
g/d with a maximal LDL-C decrease of 8-14%.(Hendriks and Weststrate 1999, Katan et al 2003,
Law 2000) The meta-analysis of Moruisi et al. was restricted to hypercholesterolemic trials only
(four trials) but reached relatively the same conclusion: 2.3 g/d of phytosterols for 6.5 weeks
lowered TC and LDL-C by 7 to 11% and 10-15%, respectively.(Moruisi et al 2006) This is in
agreement with the 2.15 g/d phytosterol dose calculated from the 8.8% maximal LDL-C decrease
obtained from the meta-analysis LDL-C dose-response curve modeled by Demonty et
al.(Demonty et al 2009) The placebo adjusted absolute LDL-C change increased with age but the
percent decrease in LDL-C did not differ, achieving a maximum effect at 2 g/d of plant sterol or
plant stanol equivalents with minimal benefit beyond 2.5 g/d (phytosterol ester dose is
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sometimes expressed in terms of phytosterol equivalents to remove the fatty acid contribution to
the dose weight).(Katan et al 2003) The eighty-four trial meta-analysis of Demonty et al. also
demonstrated no difference between the LDL-C lowering of free and esterified
phytosterols.(Demonty et al 2009)

Phytosterol Dose Frequency

Phytosterols have been administered within capsules, tablets, and food matrices via one
or more doses a day and have demonstrated mixed results. When soybean phytosterol esters were
incorporated into ground beef and administered once a day , TC and LDL-C were lowered by 9.3
and 14.6%,respectively(Matvienko et al 2002). However, other data demonstrate that a single
morning dose does not lower TC or LDL.(AbuMweis et al 2006) In determining the dose-curve
for LDL-C within the Demonty meta-analysis, the possibility of a dose-frequency effect upon
LDL-C lowering was examined. When multiple doses of phytosterols were consumed and
compared to single-dose treatments, LDL-C decreases with multiple doses were almost
significantly greater than during a single dose (p=0.054).(Demonty et al 2009) However, this
frequency of dose effect was confounded by dosage because multiple dose treatments tended to
administer higher doses versus single dose trials.(Demonty et al 2009)
A meta-analysis by AbuMweis et al. (2008) determined that a single morning dose did
not significantly affect LDL-C(AbuMweis et al 2008). In a trial, AbuMweis et al. (2009)
specifically compared the effects of supplementing plant sterols three times a day versus a single
dose and concluded that the a single morning dose was not as efficacious as multiple doses;
however, based upon the data and the comparison of the LDL-C values after treatment, there was
actually no difference, and the conclusion should have been equal effectiveness; however, it
should be noted that the trial only lasted six days, and this may not have been sufficient time to
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allow the frequency of dose effect to manifest.(AbuMweis et al 2009) Regardless, the frequency
of dose may contribute to 5% of the variation within LDL-C changes, whereas the dose may
account for 14%.(Demonty et al 2009) However, the results of the meta-analysis are merely
suggestive of an effect and need to be verified with appropriately controlled trials to definitely
decide the effect of consumption frequency upon LDL-C lowering capability.

Efficacy of Plant Sterols versus Plant Stanols

There are two forms of phytosterols administered to lower LDL cholesterol
concentrations: sterols and stanols. The therapeutic differences between sterols and stanols are
important to consider in order to maximize LDL-C lowering. However, there appear to be no
significant differences between the two phytosterols in their ability to lower LDL-C.(Jones and
Ntanios 1998) Hallikainen et al. demonstrated that 2 g/d of stanol ester or sterol ester as part of a
low-fat diet lowered LDL-C with statistical equivalency by 12.7% and
10.4%,respectively.(Hallikainen et al 2000) Katan et al. also concluded no therapeutic difference
between plant sterols and stanols in lowering LDL-C (Katan et al 2003).
While the equal short-term efficacy of phytosterols is commonly accepted, the equality of
plant sterols and stanols over the long-term is debated. Few studies have examined the long-term
efficacy of phytosterol supplementation. O’Neill et al. (2005) concluded in a meta-analysis of 14
trials that compared both phytosterols esters that plant stanols esters maintain their LDL-C
lowering effect over time whereas plant sterols esters do not (O'Neill et al 2005). However, the
meta-analysis used eleven trials that tested one of the phytosterols alone but only three of the
trials featured both plant sterols and stanols; thus, the conclusions are far from conclusive. None
of the three trials that compared stanol esters to sterol esters within the same study concluded that
plant stanols were superior. Of the three head-to-head trials included, both Weststrate et al. and
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Hallikainen et al. concluded no difference in LDL-C lowering between sterols and stanol esters,
whereas Jones et al. demonstrated a greater absolute reduction in LDL-C concentrations upon
plant sterol ester versus plant stanol ester treatment (Hallikainen et al 2000, Jones et al 2000,
Weststrate and Meijer 1998).
The trials included in the meta-analysis by O’Neill et al. only lasted between three and
four weeks making the ―efficacy-diminishing effect‖ suggested unfounded based upon the trials
included in the analysis. Furthermore, Hendriks et al. demonstrated that sterol esters maintained a
LDL-C lowering effect over one year (Hendriks et al). Gylling et al. demonstrated that plant
sterol and stanol esters administered over one year statistically equivalently lowered serum total
cholesterol by 4.4% and 4.2%, respectively (LDL-C was not reported) (Gylling et al 2009).
However, one long-term study in statin users resulted in a significant decrease in LDL-C of
13.1% for users of plant sterol esters but no decrease in the plant stanol treatment (De Jong et al
2008b). However, there was no control-adjusted statistical comparison between the treatments
thus any conclusion comparing the two would be circumspect, as the authors even denoted that
the study design was not to examine the difference between stanols and sterols. De Jong et al.
further noted no difference between plant sterols/stanol ester-induced LDL-C lowering in statin
users after sixteen weeks (De Jong et al 2008a). Some investigators suggested that these studies
demonstrate that there is a decrease in efficacy of phytosterols overtime; however, it is possible a
decrease in compliance is responsible for this loss of efficacy effect due to the free-living
conditions (Miettinen and Gylling 2005). Altogether there seems to be no evidence to
recommend plant stanol esters over plant sterol esters in hopes to maximize LDL-C decreases.
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Food Matrix and Background Diet

Phytosterols have been incorporated into various food matrices and tested under many
different background diets as cholesterol-lowering therapies. Specifically, phytosterols have
variably but effectively lowered LDL-C when incorporated into margarine spreads, (low-fat)
yogurt drinks, low-fat (fermented) milks, mayonnaise, salad dressings, chocolate, orange juice,
vegetable juice, hard cheese, fresh cheese, milk tea, ground beef, muffins, croissants, bread,
lemonade, vegetable oil, butter, tortilla chips, non-fat beverage, cereal, capsules, and tablets
(Demonty et al 2009). The efficacy of phytosterols appears to function independently of dietary
fat, thus there has been a movement to incorporate phytosterols into low-fat foods in order to
promote a low-fat low cholesterol diet profile to further improve health lipid profiles (Chen et al
2009).
After a four week lead-in period on a National Cholesterol Education Program Step I
diet, plant sterol esters at 1.1 g/d and 2.2 g/d lowered LDL-C by 7.6% and 8.4% (Maki et al
2001). Despite the variability of phytosterol efficacy in various food matrices, the meta-analysis
by Demonty et al. concluded that neither the fat content of the food format nor the nature of the
food as dairy or non-dairy significantly affected the LDL-C-lowering efficacy of the phytosterol
product (Demonty et al 2009). However, the comparison of solid and liquid food demonstrated a
significant effect upon the dosage curve, indicating that high phytosterol doses within solid
matrices would yield a maximum LDL-C 5.2% greater than in liquid foods, but this difference
was negligible at a dose of 2g/d (Demonty et al 2009).
The meta-analysis by AbuMweis et al. conflictingly concluded that LDL-C concentration
reductions were greater when phytosterols were incorporated into fat spreads, mayonnaise, salad
dressing, milk, and yogurt, versus croissants, muffins, orange juice, non-fat beverages, cereal
bars, and chocolate (AbuMweis et al 2008). Clifton et al. demonstrated evidence of the
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conclusion by AbuMweis that plant sterol esters have significantly different abilities to lower
LDL-C when incorporated into different low-fat food matrices: (15.9%) milk (15.9%) > yogurt
(8.6%) > bread (6.5%) = breakfast cereal (5.4%).(Clifton et al 2004) Plant stanol tablets have also
been used in statin combination trials, demonstrating a decrease in LDL-C (Goldberg et al 2006).
However, in a study comparing capsules and stanol lecithin tablets, the tablets led to a decrease in
cholesterol, whereas the capsules did not.(McPherson et al 2005) Other trials have demonstrated
that encapsulated phytosterol esters effectively lowered LDL-C.(Acuff et al 2007, Earnest et al
2007) For further reading on the incorporation of phytosterols into different food formats, see the
review by St-Onge and Jones.(St-Onge and Jones 2003)

Therapeutic Combination Strategies

For individuals that cannot achieve LDL-C goals with diet and phytosterols alone,
combination treatments have proven promising. Phytosterols have the potential to provide an
adjunct therapy for the use of statins, fibrates, omega-3 fatty acids, niacin, and bile acid bind
resins.

Statins. There is evidence that plant sterol and stanols produce an additive decrease in
LDL-C for individuals on statin therapy.(Thompson 2005) Administration of plant sterol esters to
individuals on statins has demonstrated an additional reduction in concentrations of TC by 5.77% and LDL-C by 9.1-10.3%.(Blair et al 2000, De Jong et al 2008a, Goldberg et al 2006)
However, not all data demonstrate an additive effect of phytosterols upon statin treatment. A low
dose of Simvastatin was compared to plant sterol esters alone and plant sterol esters in
combination with statin treatment, non-HDL cholesterol was lowered by 12.8% (plant sterol ester
(PSE)), 30.7% (simvastatin), and 35.4% (PSE+simvastatin) but the combination treatment did not
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differ significantly from the simvastatin treatment alone, indicating no advantage to the
combination versus simvastatin alone.

Fibrates.Fibrates are primarily used to significantly lower serum triglyceride levels up to
50%, often with the added secondary effects of increasing HDL cholesterol and reducing LDLC.(Chapman 2003) However, fibrates can negatively effect serum lipids via elevating LDL-C
levels in hypertriglyceride subjects.(Chapman 2003) Phytosterol combination with fibrates are a
possible therapeutic option to simultaneously lower triglyceride levels and LDL-C, offsetting the
variable effect of fibrates upon LDL-C.(Chapman 2003)
When plant sterols were added to the regimen of fibrate users and non-users following a
strict low cholesterol diet (NCEP step 1), TC and LDL-C reduction were 8.5% and 11.1% in
comparison to control spread reductions 0.0% and 1.3%, respectively, but there were no sideeffects or changes in HDL-C concentrations(Fabienne Nigon 2001). While this study did not
specifically examine phytosterols as an adjust therapy to fibrates, it demonstrated that
phytosterols positively impact lipid blood profiles regardless of fibrate treatment.
The only other study examining this combination is a serial treatment regime of seven
children without a control group that demonstrated progressive lowering of LDL-C by 50% as
three treatments were added: dietary intervention, sitosterol, and finally bezafibrate (Becker et al
1992). While the LDL-C concentrations of these children decreased over the study time-period, a
treatment effect cannot be concluded because the study was not controlled. However, the study
does demonstrate that combination therapy of phytosterols and bezafibrate did not produce any
side effects over the treatment period and the subsequent twenty-four months. Further research is
required to determine the effect of this combination.

Ezetimibe. This therapeutic option is prescribed for its ability to block the intestinal
absorption of cholesterol, which is believed to be mediated via the inhibition of Niemann-Pick
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C1-like 1-mediated cholesterol absorption (Betters and Yu 2009). Because both ezetimibe and
plant sterols work to block absorption of cholesterol, it is not surprising that combination
treatment with phytosterols and ezetimibe is no more effective than ezetimibe alone (Jakulj et al
2005).

Bile Acid-Binding Resin and Statins. Bile Acid Binding Resins function by promoting
bile acid fecal loss and subsequent bile acid synthesis from cholesterol. In an uncontrolled before
and after trial within hypercholesterolemic coronary patients on a low-fat, low-cholesterol diet, a
low-dose simvastatin (20mg/d) was added for three months, before the addition of a plant stanol
ester margarine for eight weeks, followed by the addition of cholestyramine (8 g/d) for another
eight weeks . The addition ofsimvastatin lowered LDL-C by 39%, phytosterols by an additional
13%, and cholestyramine, to the cumulative 67% decrease (Gylling H 2002). While the study is
not controlled and is only preliminary, more research should investigate this therapy both in the
absence and presence of statins.

Omega-3 Fatty acids. Omega-3 fatty acid supplementation use is prevalent due to the
anti-inflammatory and triglyceride-lowering capabilities of the lipids (Balk et al 2006). In
monotherapy, omega-3 (3g/d) in the form of fish oil has demonstrated the ability to lower serum
triglycerides up to 30% (NCEP 2002). When omega-3 fish oil and phytosterols were coadministered, total and LDL-cholesterol decreased statistically equivalent to sunola oil with plant
sterol esters without attenuating the fish oil serum triglyercide lowering effect or the antiinflammatory reduction of serum Tumor Necrosis Factor-α (Micallef and Garg 2008, Micallef
and Garg 2009).
Omega-3 fatty acids have also shown promise upon incorporation into the phytosterol
ester via esterification. Fish oil alone, fish oil sterol esters, and sunflower oil sterol esters were
compared in a crossover study and fish oil esters both lowered LDL-C statistically equivalently to

17
sunflower oil sterol esters and reduced serum triglycerides by 40%) compared to the olive oil
control diet (Demonty et al 2006). The reduction in serum triglycerides was greater than fish oil
by itself. When sunflower oil, olive oil, and fish oil fatty acid phytosterol esters were compared to
an olive oil control diet, there were no differences in total, LDL, or HDL cholesterol in
comparison to the olive oil diet, but the fish oil phytosterol ester group did result in significantly
lower fasting and postprandial triglycerides in comparison to the sunflower and olive oil
phytosterol esters (Jones et al 2007).

Niacin. Niacin increases HDL cholesterol by 15-30% and reduces triglycerides by
2035%.(NCEP 2002) Variably, Niacin has demonstrated some LDL-C lowering capabilities but
only at high doses that are often unmanageable due to side-effects such as flushing,
hepatotoxicity, and hyperglycemia in diabetic individuals.(NCEP 2002) Niacin not only favorably
alters the serum lipid profile but has demonstrated a reduction in carotid artery plaque progression
in individuals concomitantly on statins.(Lee et al 2009)
The combination of niacin and phytosterols has only been examined in the apoE mouse
model of atherosclerosis and demonstrates no superiority of niacin and phytosterols versus
phytosterols alone in either LDL-C lowering, serum triglyerides, HDL-C, or even lesion
size.(Yeganeh et al 2005) However, this apoE knock-out model may be insufficient in addressing
the combined action of niacin and phytosterols upon cholesterol metabolism because of the
absence of apolipoprotein E may disturb the balance of lipoprotein clearance, as apolipoprotein E
is transferable from VLDL to HDL, where the effects of its presence here are not completely
understood.(Nguyen et al 2009) Regardless, only more research will elucidate whether there are
possible clinical benefits to the combination of niacin and phytosterols.

Exercise. Because exercise has shown an ability to increase HDL-C and phytosterols do
not typically affect HDL-C concentrations, a study examined the effect of plant sterol esters and
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exercise in previously sedentary hypercholesterolemic individuals. While there is no no sterol-byexercise interaction, and thus no synergistic effect, plant sterol supplementation appeared not to
attenuate the positive HDL-C increase and TG lowering effect of the three day a week exercise
program completed under supervision.(Varady et al 2004) Other data indicate that phytosterols
may offset exercised-induced HDL increases.(Alhassan et al 2006) However, the results of
phytosterols and exercise in combination are inconsistent and require more work to determine
whether there are any consistent combination effects. For further reading on the effects of
exercise and phytosterols, see the review by Marinangeli et al.(Marinangeli et al 2006)

Predicting Efficacy Based On Individuality

Baseline Serum Cholesterol Concentration. In an effort to maximize LDL-C-lowering
efficacy, an understanding of the factors that influence the response of individuals to phytosterol
therapy must be obtained. One of the most obvious factors is the baseline cholesterol levels of
individuals and how that may influence the ability of phytosterols to have an effect upon the lipid
profile. A meta-analysis displayed a significant correlation between the baseline LDL-C and the
difference between the LDL-C change predicted (via dose) and the actual LDL-C change,
indicating that some of the variance in individual responses is due to the baseline cholesterol
values.(Demonty et al 2009) Another meta-analysis of five studies undertaken within the same
laboratory to minimize sample analysis variation, plant stanol ester consumption resulted in larger
absolute decreases in total and LDL cholesterol when patients had higher baseline serum levels
but the percent decrease of cholesterol was not affected.(Naumann et al 2008) In other words,
phytosterols reduce serum LDL-C more dramatically in individuals with higher baseline levels
but consistently decrease serum LDL-C by a relatively constant percentage.

19
Baseline Serum Plant Sterol Concentrations. Cholesterol-standardized serum plant
sterol concentrations are used as serum markers of baseline cholesterol absorption because of the
correlation between the cholesterol-adjusted values and the fractional cholesterol
absorption..(Miettinen et al 1990, Tilvis and Miettinen 1986) Because phytosterol therapy targets
systemic absorption of cholesterol, there is some evidence that individuals who have higher
baseline levels of cholesterol absorption may respond better to phytosterol treatment based upon
the inverse premise that individuals with lower cholesterol absorption respond better to statin
treatment.(Gylling and Miettinen 2002, Matthan et al 2009, Miettinen et al 1998) However, plant
sterol concentrations appear to be hereditary and may not always be indicative of cholesterol
absorption but variant function in the ATP-binding cassette sub-family G member 5/G member 8
(ABCG5/G8) that shuttles phytosterols out of the enterocyte and back into the lumen of the
intestine, preventing systemic absorption (Berge et al 2002, Graf et al 2003). This concept is
supported by the nature of the serum phytosterol response to phytosterol treatment.
Despite lowering cholesterol absorption, administration of plant sterols is known to
increase serum concentrations of plant sterols. (Katan et al 2003) In individuals on phytosterol
treatment, the nature of the relationship between serum plant sterols as biomarkers of cholesterol
absorption has changed, because the serum concentrations increase despite the decrease in
cholesterol absorption. Conversely, plant stanol therapy may not disrupt the association of
cholesterol and serum plant sterol concentrations, as stanols are known to lead to minimal
increases in serum phytosterol concentrations, whereas plant sterol supplementation substantially
increases serum plant sterol concentrations.(De Jong et al 2008b, De Jong et al , Hallikainen et al
2000, Jones et al 2000) Even at 8.8 g/d of stanol esters, serum campestanol concentrations
increased only 8.7 µg/dL after control adjustment whereas control-adjusted campesterol
concentrations decreased by 153 ug/dL (Gylling et al). While plant sterols and stanols do
consistently influence plasma phytosterol levels differently, the impact of elevated phytosterol
serum concentrations during therapy is not fully understood and warrants more study to
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determine the strength of the relationship between cholesterol absorption and serum phytosterols
during phytosterol therapy in order to justify the usage of serum phytosterols as biomarkers of
cholesterol absorption and to better manage the treatments of individuals who may or may not
respond to absorption inhibition therapy.

Apolipoprotein E Genotype. Based upon the increased proportion of apoE4 genotype
carriers among cardiovascular event cases in comparison to controls, a meta-analysis in the past
concluded that there is an association between the apoE genotype locus and cardiovascular
disease risk; apoE4 genotypes have an increased CHD risk versus apoE3 genotypes, whereas
apoE2 genotypes have a decreased risk (Wilson et al 1996). While epidemiological data
estimating the effect of the apoE genotype upon cardiovascular disease risk is commonly
accepted, the evidence supporting the association between serum lipid variation and apoE
genotype is not nearly as convincing.(Eichner et al 2002) Observational population studies have
demonstrated that apoE4 phenotypic populations have statistically higher LDL-C concentrations
than apoE3.(EJ Schaefer 1994, Howard et al 1998)
While some estimates indicate that the apoE genotype is responsible for 7% of serum
lipid concentration variations across individuals, data from the Framingham offspring study
demonstrated only a 1% variance and 2.1% variance in men and women, respectively, in LDL-C
levels in response to the apoE locus (EJ Schaefer 1994, Ordovas 2009). Vanhanen et al. indicate
that phytosterols decrease cholesterol more effectively in apoE4 genotypic individuals.(Vanhanen
et al 1993) However, the data cited demonstrated no statistical comparison between the controladjusted apoE4 and apoE3 genotypes but instead utilize a mere comparison to the control for each
genotype individually, indicating that any conclusion of that nature is pre-emptive.(Vanhanen et
al 1993) Sanchez-Muniz et al. concluded the opposite result, that phytosterol supplementation
―may be of little value in apoE4 carriers;‖ however, upon closer examination, the same faulty
comparison was made. (Sanchez-Muniz et al 2009)

21
Understanding why these conclusions were drawn aids in making sense of the rest of the
literature regarding phytosterols and apoE genotype. Plat and Mensink (2002) did not observe a
differential lowering of LDL-C based upon apoE genotype. Instead, the participants experienced
a -0.42 mmol/L decrease of LDL-C across the treatment group regardless of apoE genotype (Plat
and Mensink 2002). Geelen et al. (2002) demonstrated in a pre-trial apoE genotype screened,
cross-over study administering plant sterol esters to normocholesterolemic individuals that
despite an initial difference of elevated total cholesterol within the apoE4 group versus the apoE3
group, there were no significant differences according to apoE genotype in phytosterol-induced
cholesterol-lowering (Geelen et al 2002). Ishiwata et al. provides further evidence that phytosterol
ester cholesterol-lowering responses are not influenced by apoE genotype (Ishiwata et al).
Hallikainen et al. (2000) demonstrated that apoE4 individuals had a greater LDL-C decrease than
apoE3/3 individuals, providing some evidence of an apoE genotypic effect (Hallikainen et al
2000). Regardless, there is evidence that baseline total and LDL cholesterol serum concentrations
are lower within individuals with apoE2 alleles versus apoE3 and apo4 alleles (Nissinen et al
2008, Plat and Mensink 2002).
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IV. Safety Considerations

While the nutriceutical/function food safety literature has yet to reveal any deleterious
side effects of phytosterols and phytosterol esters (PSE), the potent LDL cholesterol-lowering
compounds do raise a few concerns. One potential negative impact of phytosterol fortification in
the food supply stems from the induced elevation of serum levels upon plant sterol
administration. Simulation studies have estimated that when multiple dietary items are replaced
with phytosterol-fortified products, the median phytosterol intake may be 5.5 g/d in men and 4.6
g/d in women but climb up to 8.6 g/d or even 13 g/d if more liberal fortification is allowed (De
Jong et al , Kuhlmann et al 2005). While the risk posed by an elevation in phytosterol
supplementation is minimal in the majority of individuals, substantial phytosterol-fortification
within food products may leave undiagnosed sitosterolemic individuals with a much higher risk
of premature atherosclerosis due to the acceleration of serum phytosterol accumulation upon
phytosterol-fortified food intake (Fernandez and Vega-Lopez 2005). The risk of phytosterol
plasma elevation in sitosterolemic individuals will not be covered further in this review.
However, it is worthy to note that even in unaffected individuals, serum phytosterols increase
upon plant sterol intake but not upon plant stanol intake (Fernandez and Vega-Lopez 2005,
Sudhop and von Bergmann 2004).
While the impact of elevated phytosterols is not completely understood, incorporation
into aortic plaques is strongly associated with the proportion of serum phytosterols to cholesterol
(Helske et al 2008). Furthermore, oxidized phytosterols are detected in the serum of
sitosterolemic patients in a higher percentage than cholesterol, suggesting an increased
atherogenicity (Plat et al 2001). However, the physiological relevance of the effects of oxidized
phytosterols have yet to be fully elucidated. Regardless, the substantial decrease in the LDL-C
concentration, which has demonstrated reliable atherogenicity, should potentially offset the
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minimal (in magnitude comparison) increase in serum plant sterol levels despite the uncertainty
of their atherogenicity.
After long-term consumption, plant sterol enriched products elevate serum plant sterol
concentrations in humans (Fransen et al 2007). Elevations of sitosterol concentrations may be
associated with an increased occurrence of major coronary events in men at high risk for CHD
(Assmann et al 2006). However, in one animal study, the presence of foam cells in the aortic
arch showed an inverse relationship with dietary plant sterol esters (PSE) (P<0.0001), indicating
that PSE may actually inhibit atherosclerotic development (Ntanios et al 2003). However, βsitosterol was shown to cause apoptosis in human abdominal aorta endothelial cells (stronger
toxic effect than cholesterol), indicating an increase in atherosclerotic risk but also a decrease in
the viability of cancer cells (Rubis et al 2008).
Oxyphytosterols, the oxidization product of phytosterols, are another safety concern, as
oxidized cholesterol is important in the genesis and progression of atherosclerosis. However,
oxyphytosterols have been implicated to not be deleterious and may even have beneficial
biological properties by LXR activation and subsequent expression regulation of the ABC gene
family, resulting in decreased cholesterol absorption via ABCG5/G8 downregulation
(Hovenkamp et al 2008). Lastly, plant sterols and stanols seem to evoke no negative drug
interaction when administered and do not increase the risk of gallstone formation (Miettinen et al
2000, Vanstone et al 2002).
While there are possible detrimental impacts of phytosterol therapy, when viewed in lieu
of the more substantiated and consistent reduction in cardiovascular disease risk (mediated by
phytosterol-induced LDL cholesterol-lowering), the apparent risks of phytosterols are outweighed
by the positive therapeutic benefit of reducing LDL cholesterol levels. However, more research
needs to investigate the effect of plasma phytosterol concentration elevations following
phytosterol treatment and the potential disease risk incurred. Potential problems of elevated plant
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sterols are considered further in several reviews and will not be considered further here (Patel and
Thompson 2006, Sudhop and von Bergmann 2004).

Serum Carotenoids and Lipid-soluble Vitamins

Phytosterol administration has often resulted in reductions in total lycopene and βcarotene plasma concentrations at the recommended dose, indicating a potentially detrimental
side-effect in normocholesterol and hypercholesterolemic individuals (Katan et al 2003). Many
investigators have expressed serum lipid-soluble vitamins and carotenoids in terms of lipidstandardized measures, often serum total cholesterol or combined total cholesterol and
triglycerides (Christiansen et al 2001, Davidson et al 2001, Hallikainen et al 1999, Hallikainen
and Uusitupa 1999, Hallikainen et al 2000, Hendriks and Weststrate 1999, Judd et al 2002, Maki
et al 2001, Mensink et al 2002, Plat et al 2000, Raeini-Sarjaz et al 2002). While this adjustment is
appropriate in examining the potential protective effects of carotenoids and fat soluble vitamins
against the oxidation of LDL, it does not display the total serum concentrations available for
delivery to tissues.
When considering the effect of phytosterols upon serum carotenoids and fat-soluble
vitamins, both expressions should be displayed in order to gain insight both into oxidative
potential of LDL and the possibility of nutrient deficiencies, as one measure may be significantly
affected by phytosterol treatment whereas the other may not. However, this convention has not
been followed. Noakes et al. briefly mentioned the statistically significant reduction in total
plasma concentrations of α-tocopherol and carotenoids, but displayed the lack of difference
between control for the lipid-standardized measures, and inappropriately concluded that plasma
carotenoid concentrations were maintained with dietary advice to increase intake of vegetables
(Noakes et al 2002). The proper conclusion was that plasma carotenoid concentrations were
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reduced but their lipid-standardized measures were not. However, in three reviews this was
reported as maintaining plasma carotenoid concentrations with no clarification that only lipidstandardized concentrations of carotenoids were maintained but not total serum levels (Berger et
al 2004, Moreau et al 2002, Plat and Mensink 2005).

Phytosterol Effect on Total Lipid-Soluble Vitamins and Carotenoids. In considering
total carotenoid and vitamin status, lipid-standardizing serum concentrations are inappropriate
because they do not quantify the availability of the compound for delivery to tissues. According
to the analysis of eighteen trials in meta-analysis by Katan et al., an intake of 1.5 g/d or more of
phytosterols lowers α-carotene, β-carotene, and lycopene serum concentrations and thus total
carotenoid serum status (Katan et al 2003). In many clinical trials, phytosterol total serum
concentrations of carotenoids and/or tocopherol decreased but lipid-standardized concentrations
did not (Davidson et al 2001, Hallikainen et al 1999, Hallikainen and Uusitupa 1999, Hallikainen
et al 2000, Hendriks et al , Plat et al 2000). Decreases in carotenoids normally remain within the
limits, but may be important for individuals with low intake (Judd et al 2002).
Despite the carotenoid-lowering effect of phytosterols, serum levels of retinol, indicating
vitamin A status, have demonstrated no change (Christiansen et al 2001, Davidson et al 2001,
Hallikainen and Uusitupa 1999, Hallikainen et al 2000, Judd et al 2002, Maki et al 2001, Mensink
et al 2002, Ntanios et al 2002, Plat et al 2000, Raeini-Sarjaz et al 2002). While carotenoid
systemic availability consistently decreases upon phytosterol supplementation, the presence of
carotenoid-derived retinol is not modified, suggesting adequate nutrient status throughout the
phytosterol treatment. For individuals with a greater need for vitamin A, such as pregnant and
lactating women and children, the decrease in plasma carotene is an important concern (Richelle
et al 2004).
β-carotene contributes to about 10-15% of the Recommended Daily Allowance of
vitamin A via conversion, but the extent of this conversion depends to a substantial degree upon
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the food matrix and the diet of the individual.(Strobel et al 2007, Wang et al 2008) However, in
individuals with retinol concentrations of 1.7 umol/L, β-carotene conversion to vitamin A was
estimated to be 80% when consumed in the form of spirulina.(Wang et al 2008) Katan et al.
concluded that even though low carotenoid levels have been associated with increased cancers,
macular degeneration, and cardiovascular disease, the risks have yet to be backed by evidence
beyond epidemiological trials.(Katan et al 2003)
Some investigators have demonstrated that carotenoids themselves are involved in
immune function, thus decreased serum carotenoid concentrations may have an impact on health
over the long-term, regardless of the impact upon serum concentrations retinol.(Palozza et al
2004, Ruhl 2007, Sharoni et al 2004) However, the physiological relevance of carotenoidmediated functions independent of retinol need to be further examined to determine whether the
impact of phytosterols on circulating carotenoid levels as any clinical importance. A six month
trial investigating phytosterols demonstrated LDL-C lowering without a decrease in total serum
carotenoid concentrations when administered as microcrystalline phytosterols.(Christiansen et al
2001) However, serum retinol concentrations were not evaluated. Because of the consistent
carotenoid-lowering effect of phytosterols, long-term trials should evaluate both carotenoid and
retinol status to ensure that there are no physiologically relevant negative long-term effects of
phytosterols.

Potential Effect of Phytosterol on Serum Antioxidants and LDL Oxidation. Because
carotenoids and tocopherols are primarily transported within lipoproteins, adjusting the serum
concentrations in relation to the total serum cholesterol or serum lipid (total cholesterolipid +
triglycerides) yields a lipid-standardized measure that relates the amount of the particular
carotenoid to the lipid within the serum lipoproteins class responsible for its transport (Richelle et
al 2004, Traber et al 1994, Wang et al 2007). While this does not provide a measure of serum
carotenoid status, it is an appropriate approach when considering the antioxidant density of
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lipoproteins and their subsequent potential to reduce the oxidative susceptibility of LDL. In some
studies, the phytosterol treatment decreased both the lipid-standardized measure and the total
serum concentrations, indicating both a reduction in carotenoid and vitamin status and a decrease
in antioxidant density within lipoproteins.(Hendriks and Weststrate 1999, Judd et al 2002, Maki
et al 2001, Mensink et al 2002)
However, while total serum carotenoids have been found to be related to oxidized LDL in
older women in epidemiological studies, there is minimal evidence supporting this concept.(Beck
et al 2008) LDL isolated from subjects on a high carotene diet failed to produce a protection
against lipid peroxidation; in fact, only the tomato juice group (high in lycopene) demonstrated an
anti-oxidative protective effect against LDL oxidation.(Bub et al 2000) A similar trial with a
vitamin mix supplement demonstrated that antioxidants did not decrease LDL oxidation.(Abbey
et al 1993, Brude et al 1997) Furthermore, a meta analysis found no link to support use of dietary
antioxidants to prevent age-related macular degeneration, whereas another study found that only
lutein plus zeaxanthin was associated to intima-media thickness—not β-carotene, retinol, or αtocopherol (Chong et al 2007, Iribarren et al 1997). The data demonstrating any protective effect
of anti-oxidants against LDL oxidation are unconvincing. Regardless, when examining the impact
of phytosterol administration upon the anti-oxidant density of LDL, the lipid-standardized
measure is appropriate.

Prevention of Carotenoid-Lowering Effect. In a bioavailability study within
normocholesterolemic men, plant sterol equivalents as either free or esterified sterols both
reduced both the area-under the curve (AUC) and the maximum concentration for [2H8]-βcarotene and retinyl palmitate over nine hours without a change in respective triglyceride
concentrations, but the effect of plant sterol esters was significantly greater than those of the free
sterols (AUC-β-carotene reduced 57% by esters and 48% by free sterols).(Richelle et al 2004)
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In one study designed to determine if increasing dietary carotenoids via increased
vegetable consumption was sufficient in offsetting phytosterol-induced carotenoiod lowering,
change was observed in the absolute plasma concentrations but reported in terms of the lack of
change in lipid standardized values (TC+TG standardized). However, the plasma concentrations
of lycopene, α/β carotene, and even the fat-soluble vitamin α-Tocopherol decreased significantly
(p<0.001) but the reported standardized measurements did not demonstrate this difference
(Noakes et al 2002). Furthermore, the plasma lutein and α/β carotene levels increased in the
control subjects from baseline, indicating that the subjects were increasing consumption of
vegetables in a sufficient manner to induce significant serum carotenoid changes. However, upon
standardization of these values, even these differences disappeared, which seems contrary with
the absence of change in cholesterol levels in the control due to the lack of treatment.(Noakes et
al 2002)
When hypercholesterolemic men consumed a low-fat 1.3 g/d plant sterol ester spread,
dietary β-carotene serum concentrations decreased despite the dietary advice to increase
carotenoid intake.(Colgan et al 2004) Under a controlled diet, 1.92 g/d of sterol esters and 1.76
g/d of stanol esters, neither the lipid-standardized or the total serum concentrations of retinol, αtocopherol, γ-tocopherol, β-carotene, and other carotenoids were measured and shown to not
decrease significantly according to either treatment versus the control.(Raeini-Sarjaz et al 2002)
However, phytosterol therapy targets free-living individuals without dietary supervision, thus
another approach to the prevention of phytosterol-induced serum carotenoid change must be
implemented for feasible prevent in the population. However, in one study incorporating 0.33 and
0.59 mg/serving of β-carotene into the sterol ester treatment croissant and muffin but not the
control (α-tocopherol done the same, half as much in the control), TC and LDL-C were lowered
significantly by 0.38 mmol/L and 0.36 mmol/L, respectively, and the β-carotene, α-carotene,
lycopene, α-tocopherol, and γ-tocopherol were not significantly reduced in comparison to the
control, indicating that co-administration of carotenoids and phytosterols does not lower the net
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carotenoid concentration in the serum regardless of its historical ability to decrease its
absorption(Quilez et al 2003b). The data suggest that carotenoid supplementation should
accompany phytosterol administration to minimize potential safety issues.

Pregnancy and Breastfeeding

A phytosterol-rich maternal diet increases the breast-milk phytosterols, and,
subsequently, infant plasma phytosterols.(Mellies et al 1978) Because phytosterols are absorbed,
albeit at a low level, and subsequently are present in breast-milk, the potential for phytosterol
side-effects during pregnancy and post-partum care must be considered.(Ostlund et al 2002a)
Phytosterol administration during pregnancy did not significantly affect serum LDL-C or total
cholesterol during the first or third trimester of pregnancy or even during one month post-partum
in a study with plant stanol esters (Benecol).(Laitinen et al 2009) Furthermore, the infants of the
phytosterol group had significantly lower cholesterol-standardized serum β-carotene levels in
comparison to the control infants at one month, but this difference disappeared after six months
.(Laitinen et al 2009) The total serum β-carotene levels did not differ at one or six months of age,
indicating adequate β-carotene status. However, lipid-standardized β-carotene levels were lower
at one month than the control, an effect that disappeared by six months. Furthermore, plant stanol
ester spread did not impact infant growth or gestation length.(Laitinen et al 2009) However, more
research needs to demonstrate that the value of phytosterol supplementation during pregnancy
outweighs the added risk of lipid-standardized β-carotene deficiency in neonates, but in the
meantime phytosterols should not be recommended during pregnancy until therapeutic benefits
are demonstrated.
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Study I.
Crude and Refined Black Raspberry Seed Oils Significantly Lower
Triglycerides and Moderately Affect Cholesterol Metabolism in Male
Syrian Hamsters

Elevated plasma lipid concentrations are a major risk factor for atherosclerotic disease,
including both low-density lipoprotein (LDL) cholesterol and triglyceride concentrations (Austin
et al 1998, NCEP 2002). While potential severe side-effects accompany drug therapy, dietary
components often elicit similar therapeutic benefits with minimal added risk of adverse events.
In this study, we examined the ability of crude and refined black raspberry seed oil (Rubus
occidentalis) to lower lipids in a hamster model of atherosclerosis fed a high-cholesterol (0.12%
g/g), high fat (9% g/g) diet for four weeks. Black raspberry seeds are a species of caneberry seeds
composed of high levels of polyunsaturated fatty acids, polyphenolic compounds (primarily
ellagic acid), phytosterols, and α- and γ-tocopherols, yielding a promising potential lipid lowering
dietary therapeutic (Bushman et al 2004).
Linoleic acid, an omega-6 fatty acid, and α-linolenic acid, an omega-3 fatty, are present
in black raspberry seed oil (RSO) in high concentrations, thus the oil is a good terrresterial source
of omega-3 fatty acids. Omega-6 polyunsaturated fatty acids have demonstrated the ability to
lower LDL and HDL cholesterol concentrations (Kurushima et al 1995, Lecker et al 2010, SiriTarino et al), whereas omega-3 fatty acids are often used to reduce triglycerides in an effort to
prevent and minimize risk of cardiovascular and diabetic disease accompanying
hypertriglyceridemia (National Cholesterol Education Program NCEP 2002). While omega-6
fatty acids exert a regulatory role upon cholesterol metabolism, omega-3 fatty acids exert more of
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an effect upon triglyceride concentrations, an effect believed to be mediated by alterations in
triglyceride-rich very low-density lipoprotein (VLDL) secretion mediated by inhibition of sterol
regulatory element binding protein-1 effector genes (Clarke 2001, Zuliani et al 2009) and
hepatic β-oxidation via activation of peroxisome proliferator-activator receptor-α (PPAR-α)
(Clarke 2001, Delarue et al 2004). Omega-6 polyunsaturated fatty acids have also demonstrated
an ability to decrease VLDL lipid concentrations (Sessions and Salter 1994) and prevent hepatic
LDL receptor gene suppression upon elevated hepatic cholesterol concentrations, thereby
increasing hepatic uptake of LDL from the plasma (Kurushima et al 1995). Subsequently, when
polyunsaturated fat sources replace saturated fatty acid-rich foods, both low-density lipoprotein
cholesterol and high-density lipoprotein cholesterol are lowered in both both hamsters (Dorfman
et al 2005) and humans (Kralova Lesna et al 2008).
Raspberry seed oils also contain high levels of the polyphenol ellagic acid (Bushman et al
2004). While the antioxidant capacity of ellagic acid has been demonstrated (Hassoun et al 1997,
Priyadarsini et al 2002), few investigations have examined the ability of polyphenol to modulate
lipid concentrations. Within alcohol-induced liver steatotic rats, ellagic acid administration
reduced the accumulation of lipids in the liver (Devipriya et al 2008). Within 0.5% cholesterol
supplemented rabbits, 1% (w/w diet) ellagic acid significantly lowered plasma triglycerides and
total, LDL, and HDL cholesterol in comparison to diets without ellagic acid (Yu et al 2005),
indicating that ellagic acid may ellict lipid lowering effects; however, the full impact of ellagic
acid requires more investigation.
While tocotrienols are not present to any great extent, tocopherols are highly
concentrated in food products in black raspberry seed oils (Adhikari et al 2008). Tocopherol
supplementation has demonstrated an inverse association with intima media thickness in
epidemiology studies (Azen et al 1996, Rimm et al 1993). Tocopherols have been hypothesized
to contribute to atherosclerotic disease prevention through the reduction of inflammation via their
antioxidant characteristics (Devaraj et al 2007), but conflicting results have been obtained in
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clinical trials (Albertini et al 2002, Bleys et al 2006). It is possible that the HDL lowering effect
observed in the current study was exacerbated by tocopherols, which have shown some ability to
downregulate cholesterol synthesis and HDL cholesterol secretion from Caco-2 cells (Landrier et
al). However, α-tocopherols have shown no effect either plasma cholesterol and triglyceride
concentrations or aortic foam cell accumulation in atherogenic diet fed hamsters (Parker et al
1995). Overall, there is little evidence supporting a therapeutic effect of vitamin E intake above
the recommended dose on lipid metabolism (Schneider 2005). Regardless, the presence of
tocopherols in the RSOs may contribute additively or synergistically to their overall lipid
lowering efficacy.
The current study investigated black raspberry seed oil enriched in polyunsaturated fatty
acids, ellagic acid, phytosterols, and α- and γ-tocopherols in both crude and refined oil form to
determine the overall lipid lowering of this potential dietary therapeutic. High cholesterol diets
supplemented with crude and refined black raspberry seed oils, or coconut oil (atherogenic
control) were compared to a soybean oil diet without cholesterol in order to examine whether the
crude and refined raspberry seed oil (RSO) treatments significantly altered lipid metabolism
equivalently.
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Methods and Materials

Thirty-seven male Syrian hamsters (Charles River Labs, Wilmington, MA) weighing 5570 g were housed individually in polycarbonate cages with a bedding of sawdust. Upon arrival,
the hamsters were randomly divided into groups of 9-10 hamsters, allowed free access to water,
and fed dietary treatments ad libitum throughout the four week study. Hamsters were kept in a
humidity controlled room at 25°C, using a 12-h light/dark cycle for the duration of the study. All
procedures were approved by the Institutional Animal Care and Use Committee of the University
of Nebraska.
Hamsters were fed a modified AIN-93M diet supplemented with soybean oil, coconut oil,
refined raspberry seed oil, or crude raspberry seed oil. Ingredients were mixed manually to
achieve a fine blend in proportions outlined in Table 1. The soybean oil diet fatty acid intake was
entirely from soybean oil (9% g/g), which provides all of the needed linoleic and linolenic
essential fatty acids. However, because coconut oil does not have these essential fatty acids, 1%
of the diet was soybean oil to ensure adequate linoleic and linolenic acid intake and 8% of the diet
was provided by saturated fatty acid-rich coconut oil. Because black raspberry seed oil is rich in
linoleic and α-linolenic acids (Table 2), the raspberry seed oil (RSO) diets consisted of a 9% RSO
intake without soybean oil supplementation. The soybean oil diet was not supplemented with
cholesterol to provide a basal lipid metabolism control for comparison, whereas the coconut oil
and the RSO diets were supplemented with 0.12% (g/g) cholesterol. The coconut oil diet served
as the atherogenic control. Each diet was portioned into two 1 kg bags and stored at -20°C. The
AIN-93 mineral and vitamin mixes, casein, dextrinized cornstarch, and fibers were purchased
from Dyets, Inc. (Bethlehem, PA). Choline bitartrate, L-cystine, and cholesterol were purchased
from Sigma Chemicals (St. Louis, MO). Cornstarch, sucrose, and soybean oil were purchased
from a local grocery store. Black raspberry seed oils were extracted via hot hexane, and the
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refined oil was processed via acidification, degumming, bleaching, clay filtering, and
deodorization as detailed in a prior publication (Adhikari et al 2008). The fatty acid composition
of the raspberry seed oils was obtained via GC FAME analysis as described previously (Oh et al
2007) to determine whether there was a difference in the fatty acid or the phytosterol composition
of the oil (Table 2). Notably, the crude and refined oils contained high levels of linoleic acid
(omega-6), 54.3% ±0.02% (crude) and 55.3% ± 0.06% (refined), and α-linolenic acid (omega-3),
32.2% ± 0.04% (crude) and 31.4% ± 0.16% (refined). The crude and refined raspberry seed oils
contained 1268 ± 61 mg/kg and 1307 ± 89 mg/kg of sitosterol, the major phytosterol commonly
present in vegetable oils. The obtained phytosterol concentrations were substantially lower than
0.73-1.10% phytosterol composition published by Winton and Winton in 1935 (Winton and
Winton 1935). However, the statistically equivalent fecal phytosterol excretion support the
compositional data obtained. While there were no differences between the oils in the parameters
measured, both oils contained high levels of polyunsaturated fatty acids and sitosterol. Previous
analysis of black raspberry seed oils extracted and/or processed in the same fashion demonstrated
a significantly lower amount of total tocopherols in the refined oil (142 mg/100g oil) versus the
crude oil (175 mg/100g oil) (Adhikari et al 2008).
Hamster body weights and food intakes were recorded weekly, and feces were collected
during week four for pooled 7-day analysis of bile acid and sterol excretion. On the final day of
the study (day twenty-eight), the animals were euthanized with CO2 and blood was collected by
cardiac puncture using 10 mL syringes containing 10 mg EDTA and immediately placed on ice
after opening the thoracic cavity via incision. Within hours, plasma was isolated by
centrifugation at 1000 × g for 30 minutes at 4°C and either analyzed within four days or stored at
-80°C until further analysis. Livers were excised, weighed, and stored at -80°C prior to analysis.

35

Table 1. Diet composition
SO

CO

Refined RSO

Crude RSO

g/kg
Cornstarch

415.7

414.5

414.5

414.5

Dextrinized cornstarch

155.0

155.0

155.0

155.0

Casein

140.0

140.0

140.0

140.0

Sucrose

100.0

100.0

100.0

100.0

Coconut oil

---

80.0

---

---

Soybean oil

90.0

10.0

---

---

Raspberry seed oil, refined

---

---

90.0

---

Raspberry seed oil, crude

---

---

---

90.0

Insoluble fiber (cellulose)

40.0

40.0

40.0

40.0

Soluble fiber (guar gum)

10.0

10.0

10.0

10.0

---

1.2

1.2

1.2

AIN-93 mineral mix

35.0

35.0

35.0

35.0

AIN-93 vitamin mix

10.0

10.0

10.0

10.0

L-Cystine

1.8

1.8

1.8

1.8

Choline bitartrate

2.5

2.5

2.5

2.5

Cholesterol

SO = soybean oil; CO = coconut oil; RSO = raspberry seed oil.
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Table 2. Raspberry Seed Oil Lipid Composition
SO1

CO1

Fatty Acids

Refined RSO

Crude RSO

% (w/w)

Caproic

C6:0

N/D2

0.5

N/D

N/D

Caprylic

C8:0

N/D

7.8

N/D

N/D

Capric

C10:0

N/D

5.8

N/D

N/D

Lauric

C12:0

N/D

43.2

N/D

N/D

Myristic

C14:0

0.1

17

N/D

N/D

Palmitic

C16:0

10.7

8.6

1.9 ± 0.01

2.1 ± 0.00

Palmitoleic

C16:1

0.1

N/D

N/D

N/D

Margaric

C17:0

0.1

N/D

N/D

N/D

Stearic

C18:0

4.4

2.9

0.8 ± 0.05

0.9 ± 0.00

Oleic

C18:1n-9

20.1

6.5

9.7 ± 0.05

9.7 ± 0.03

Vaccenic

C18:1 n-7

1.2

0.1

N/D

N/D

Linoleic

C18:2

53.3

1.6

55.3 ± 0.06

54.3 ±0.02

Linolenic

C18:3

8.2

N/D

31.4 ± 0.16

32.2 ± 0.04

Arachidic

C20:0

0.3

N/D

0.4 ± 0.02

0.4 ± 0.00

11-Eicosenoic

C20:1

0.2

N/D

0.2 ± 0.03

0.2 ± 0.02

11,14-Eicosadienoic C20:2

N/D

N/D

0.1 ± 0.05

0.1 ± 0.01

Docosanoic

0.4

N/D

0.2 ± 0.01

0.2 ± 0.00

C22:0

Phytosterols

mg/kg of RSO

Sitosterol

1242

639

1307 ± 89

1268 ± 61

Total Phytosterols3

2408

1177

1307 ± 89

1268 ± 61

SO = soybean oil; CO = coconut oil; RSO = raspberry seed oil; 2N/D = not detected. RSO values
are means  SEM, n = 3. SO and CO analyzed in singlet, n =1. ANOVA Statistical comparison was
performed for sitosterol analysis only and no treatment differences were detected (P>0.05)
1
The SO and CO analyzed were standard stocks used in our laboratory in place of the exact oil used
in the diet and are provided for subjective comparison. The percentages are not adjusted for
unidentified peaks and thus represent total peak area percentage obtained from GC analysis.
3
Sum of brassicasterol, campesterol, stigmasterol, sitosterol, and Δ5-avenasterol.
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Plasma Lipid Analysis. Plasma concentrations of total cholesterol and triglycerides were
analyzed in duplicate after 1:10 dilution using previously published enzymatic assays (Carr et al
1993). Regents were purchased from Roche Diagnostics, Indianapolis, IN and the plates were
incubated at 37°C for ten minutes before the absorbances were measured at 505 nm. High-density
lipoproteins (HDL) were isolated via precipitation of apo-B containing lipoproteins using a 1:1
dilution with 100 µL of plasma and 100 µL of precipitating reagent (Thermo Electron Corp,
Melbourne, Australia) and HDL cholesterol was quantified in duplicate after 2:5 dilution in
deionized water via measuring the total cholesterol of the supernatant (Carr et al 1993).
Following incubation of ten minutes at 37°C, the samples were read at 505 nm. Plasma non-HDL
cholesterol levels were calculated by subtracting plasma HDL cholesterol from plasma total
cholesterol.
Liver Lipid Quantification. Approximately 0.3-0.4 g of frozen liver was minced and the
exact weight recorded prior to an overnight chloroform/methanol (2:1, v/v) Folch extraction
(Folch et al 1957) and subsequent heating for one hour at 50°C to ensure complete extraction.
The samples were quantitatively filtered (rinsed three times with excess chloroform/methanol)
through Whatman #41 filter paper into graduated conical screw cap tubes and the total volume
was brought to 10 mL. After adding 2.0 mL of 0.88% KCl, the samples inverted five times to
ensure mixing before complete phase separation via brief centrifugation. The lower phase
volume was recorded before the upper phase was aspirated and discarded. Total cholesterol, free
cholesterol, triglycerides and phospholipids were quantified enzymatically after solubilization of
0.5 mL lipid phase aliquots in Triton X-100 using the procedure of Carr et al. (Carr et al 1993).
Total cholesterol and triglyceride regents were the same as used in the plasma analysis, whereas
the free cholesterol and phospholipid reagents were purchased from Wako Chemicals (Richmond,
VA). Total cholesterol and free cholesterol aliquots were analyzed in directly, whereas
triglycerides and phospholipids were diluted 2:5 in deionized water prior to analysis. All samples
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were analyzed in duplicate and incubated for ten minutes at 37°C after the addition of the
appropriate reagent. Liver esterified cholesterol was quantified as difference between the obtained
total cholesterol and free cholesterol.
Fecal Bile Acid and Neutral Sterol Extraction. Bile acids and neutral sterols were
extracted individually on different occasions in the same manner from feces using
chloroform/methanol (2:1, v/v) according to Folch et al (Folch et al 1957). Approximately 100
mg of ground fecal matter was placed in screw-top tubes, and the exact weight was recorded. 5αCholestane was added to only the neutral sterol quantification samples as an internal standard to
account for sterol loss during sample analysis. To ensure extraction efficiency, 0.7 mL of 0.5M
HCl was added followed by 10 mL of chloroform/ methanol (2:1, v/v) to initiate the extraction.
The samples were capped, vortexed, left overnight, and heated for fifteen minutes to ensure
complete lipid extraction. After 2.0 mL of 0.88% KCl was added to each sample, the tubes were
inverted several times and centrifuged for ten minutes at 1000 × g to induce phase separation. For
the bile acid extraction, the upper phase containing the bile acids was transferred to a clean tube
without disturbing the lower phase. The lower phase was washed to recover any residual bile
acids with an additional 3 mL of chloroform/methanol/water (3:48:47). Samples were inverted
and centrifuged as before, and the upper phase was added to the bile acids from the first transfer.
During the neutral sterol analysis, the upper bile acid phase was aspirated and discarded, and the
lower phase was transferred to a new tube via decanting.
Bile Acid Analysis. Aliquots of the recovered upper phases were evaporated at 50°C
under nitrogen in standardized glass cuvets to remove the solvent prior to quantification using the
3-hydroxysteroid dehydrogenase method previously published (Sheltawy and Losowsky 1975).
The samples were re-solubilized in 100 µL of methanol and 3.5 mL of -NAD in pH-adjusted
CAPS buffer (0.2 mg/mL; pH 10.8) was added. After vortexing, the background absorbance at
340 nm was read and 0.4 mL of 3-hydroxysteroid dehydrogenase (0.75 units/mL of 0.01 M
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phosphate buffer, pH 7.2) was added, followed by sample incubation at 37C for thirty minutes.
The absorbance was read again at 340 nm, and the difference between the post-enzymatic
reaction and background was used to calculate the total bile acid concentration in the aliquots
utilizing the 0.01 M cholic acid 0.1-0.5 mmol/assay standard curve dilution after adjusting for the
difference in sample volume after the addition of the enzyme. Fecal bile acid excretion was
calculated from the fecal concentration and the daily fecal output per 100g body weight. -NAD,
CAPs, Cholic acid, and 3-hydroxysteroid dehydrogenase were all purchased from SigmaAldrich (St. Louis, MO, USA).
Fecal Neutral Sterol Quantification. The collected lower phase was also evaporated at
50°C under nitrogen to remove the chloroform, utilizing excess solvent to concentrate the
samples at the bottom of the tubes. Saponification was initiated with the addition of 1 mL of 1.0
M KOH in methanol. The tubes were flushed with nitrogen, capped, and heated at 50°C for one
hour with frequent vortexing.After 1 mL of distilled water was added, samples were vortexed.
Non-saponifiables were extracted via the addition of 3 mL of hexane, subsequent vigorous
shaking for thirty seconds, brief centrifugation at 1000 x g, and the transferring of the upper
hexane phase to new screw-top glass tubes. The lower phase was washed with an additional 3 mL
of hexane, the samples were mixed vigorously, the phases separated via centrifugation, and the
neutral sterol containing upper phase was added to the previously transferred hexane phase.
Samples were dried under nitrogen at 50°C and were redissolved in equivalent volumes of hexane
and quantified by gas chromatography using an AT-5 capillary column (Alltech, Deerfield, IL)
with a 15.0°C/minute temperature ramp from an initial one minute hold at 270°C to a final hold at
300°C of fourteen minutes; an inlet temp of 270°C and a Flame Ionizing Detector temperature of
300°C.
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Results

Dietary group hamster body weights were not significantly different during the study
(Table 3). Food take did not differ except during the first week when the crude raspberry seed oil
diet food intake was significantly lower than the soybean oil and coconut oil diets but not the
refined raspberry seed oil diet. Because of the absence of any differences in intake during any
other weeks, the effect was presumed to be due to initial adjustment to the diets (Table 4).
Plasma lipid analysis demonstrated significantly lower plasma total cholesterol
concentrations in both raspberry seed oil (RSO) diets in comparison to the coconut oil
atherogenic control but were not reduced to the extent of the soybean oil diet (Table 5). NonHDL cholesterol concentrations were significantly higher and statistically equivalent in the
coconut oil, crude RSO, and refined RSO diets than the soybean oil diet (Table 5). HDL
cholesterol was statistically the highest in the coconut oil dietary group (4.07 ± 0.26 mmol/L) in
comparison with the statistically equivalent crude and refined RSO diets (2.16 ± 0.10 mmol/L and
2.19 ± 0.15 mmol/L, respectively) (Table 5). The soybean oil group had the significantly lowest
HDL cholesterol concentration of 2.09 ± 0.11 mmol/L. Plasma triglyceride concentrations were
statistically and equivalently lower in the soybean oil (1.62 ± 0.16 mmol/L), crude RSO (1.75 ±
0.20 mmol/L), and refined RSO (2.32 ± 0.31 mmol/L) diets in comparison to the coconut oil diet
(3.28 ± 0.51 mmol/L) (Table 5).
Liver masses were significantly lower in the soybean oil positive control group (4.50 ±
0.17 g/100 g of body weight) compared to the statistically equivalent cholesterol supplemented
diets (Table 6). Liver free cholesterol concentrations were statistically higher and equivalent
among the coconut oil (5.7 ± 0.2 µmol/g), refined RSO (6.1 ± 0.1 µmol/g), and crude RSO (6.0 ±
0.2 µmol/g) diets in comparison to the soybean oil diet (4.7 ± 0.1 µmol/g) (Table 6). The refined
RSO diet (25.6 ± 1.4 µmol/g) had the statistically highest liver esterified cholesterol
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concentration in comparison all other diets, while the the statistically equivalent crude RSO (21.2
± 2.1 µmol/g) and coconut oil (18.2 ± 1.5 µmol/g) diet means were significantly lower than the
the soybean oil diet (0.6 ± 0.1 µmol/g) (Table 6). Liver triglycerides were significantly elevated
with the coconut oil diet (7.8 ± 0.7 µmol/g) in comparison to all other diets. The soybean oil diet
(6.1 ± 0.4 µmol/g) liver triglyceride concentration was significantly lower than the coconut oil
diet, statistically equivalent to the refined raspberry seed oildiet (5.0 ± 0.3 µmol/g) but higher
than the crude raspberry seed oil diet (4.2 ± 0.2 µmol/g) despite statistical equivalency between
both RSO diets (Table 6). Liver phospholipids were not significantly different between any of the
diets (Table 6).
Fecal excretion of cholesterol and cholesterol derivatives produced from microorganism
modification (neutral sterols) was equivalent among the cholesterol supplemented diets (coconut
oil and both RSO groups) but significantly higher than the soybean oil control (Table 7).
Phytosterol fecal excretion was significantly elevated with both RSO diets in comparison to the
soybean and coconut oil diets (Table 7). Phytosterol fecal excretion tended to be higher in
hamsters treated with the crude RSO diet compared to the refined RSO diet (p = 0.0505). Total
sterol excretion was significantly higher and statistically equivalent among the refined RSO and
the crude RSO diets in comparison to the coconut oil and the soybean oil groups, which did not
differ significantly (Table 7). Fecal bile acid excretion was significantly elevated in the refined
RSO diet in comparison to the other diets (Table 7). Fecal output did not differ significantly
among the groups (Table 7).
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Table 3. Hamster body weight
SO

CO

Refined RSO

Crude RSO

g
Week 0

64.4  1.5

65.4  1.0

64.6  1.1

64.8  1.6

Week 1

77.6  2.2

75.9  1.5

74.3  3.0

71.2  3.6

Week 2

91.8  4.1

89.7  1.6

92.7  3.3

86.9  6.0

Week 3

102.0  4.9

99.8  2.4

106.2  3.2

100.8  5.6

Week 4

112.7  5.5

106.9  2.5

113.9  3.1

109.9  4.7

SO = soybean oil; CO = coconut oil; RSO = raspberry seed oil. Values are means  SEM, n = 9-10.
No treatment differences were detected (P>0.05).

Table 4. Food intake
SO

CO

Refined RSO

Crude RSO

g
Week 1

53.3  2.9b

53.2  2.7b

48.2  2.8a,b

38.9  4.0a

Week 2

59.2  1.6

63.9  3.5

61.6  1.7

66.3  4.1

Week 3

63.6  4.0

63.0  2.7

63.9  2.0

65.4  1.6

Week 4

54.3  9.2

64.3  3.8

61.9  2.7

61.7  1.3

SO = soybean oil; CO = coconut oil; RSO = raspberry seed oil. Values are means  SEM, n = 9-10.
a,b
Means within a row having different superscripts are statistically different (P < 0.05).

43

Table 5 Plasma lipid concentrations
SO

CO

Refined RSO

Crude RSO

mmol/L
Total cholesterol

2.74  0.07a

6.26  0.27c

5.23  0.20b

5.04  0.27b

non-HDL cholesterol

0.65  0.09a

2.19  0.16b

2.19  0.15b

2.16  0.10b

HDL cholesterol

2.09  0.11a

4.07  0.26c

3.05  0.19b

2.88  0.25b

Triglyceride

1.62  0.16a

3.28  0.51b

2.32  0.31a

1.75  0.20a

SO = soybean oil; CO = coconut oil; RSO = raspberry seed oil. Values are means  SEM, n = 9-10.
a,b,c
Means within a row having different superscripts are statistically different (P < 0.05).

Table 6. Liver lipid concentrations
SO

CO

Refined RSO

Crude RSO

µmol/g
Total cholesterol

5.3  0.1a

24.0  1.6b

31.6  1.4c

27.2  2.2b

Free cholesterol

4.7  0.1a

5.7  0.2b

6.1  0.1b

6.0  0.2b

Esterified cholesterol

0.6  0.1a

18.2  1.5b

25.6  1.4c

21.2  2.1b

Triglyceride

6.1  0.4b

7.8  0.7c

5.0  0.3a,b

4.2  0.2a

Phospholipid

22.6  0.8

21.4  0.3

22.7  0.4

22.4  0.6

g/100 g of body weight
Liver Weights

4.50 ± 0.17a

5.50 ± 0.13b

6.01 ± 0.20b

5.73 ± 0.17b

SO = soybean oil; CO = coconut oil; RSO = raspberry seed oil. Values are means  SEM, n = 9-10.
a,b,c
Means within a row having different superscripts are statistically different (P < 0.05).
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Table 7. Fecal output and fecal sterol and bile acid excretion
SO

CO

Refined RSO

Crude RSO

µmol × day–1 × 100 g–1 body weight
Neutral sterols1

1.79 ± 0.18a

4.09 ± 0.27b

3.91 ± 0.22b

4.02 ± 0.32b

Phytosterols2

1.75  0.18a

0.72  0.06a

3.13  0.36b

4.27  0.43b

Total sterols

3.54 ± 0.27a

4.81 ± 0.29a

7.04 ± 0.45b

8.29 ± 0.68b

Bile acids

0.84  0.09a

0.89  0.07a

1.20  0.10b

0.90  0.07a

g x day-1 x 100 g-1 body weight
Fecal output

0.725 ± 0.047

0.707 ± 0.016

0.665 ± 0.038

0.707 ± 0.046

SO = soybean oil; CO = coconut oil; RSO = raspberry seed oil. Values are means  SEM, n = 9-10.
1
Sum of cholesterol, dihydrocholesterol, coprostanol, and coprostanone.
2
Sum of brassicasterol, campesterol, stigmasterol, sitosterol, and sitostanol
a,b
Means within a row having different superscripts are statistically different (P < 0.05).
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Discussion

The aim of this study was to examine the ability of black raspberry seed oil to lower
lipids within hamsters as a model of atherosclerosis and to determine whether oil processing
modifies any lipid lowering properties. Black raspberry seed oil is high in the polyunsaturated
fatty acids linoleic acid and α-linolenic acid, the polyphenol ellagic acid, phytosterols, and α- and
γ-tocopherols (Bushman et al 2004). Fatty acid analysis of the raspberry oils confirmed the high
presence of linoleic and α-linolenic acid. While the oils consisted of an array of potential lipid
modulating components, this study was not designed to test the individual contribution of each of
these components to the lipid lowering efficacy of the oils but rather to examine the combined
potential of the oil components to lower lipids depending on the extent of processing.
Despite the evidence that omega-6 polyunsaturated fatty acids lower LDL and HDL
cholesterol concentrations(Kurushima et al 1995, Lecker et al 2010, Siri-Tarino et al), the data
obtained from our study demonstrate a reduction in plasma HDL and total cholesterol
concentrations upon replacing coconut oil with black raspberry seed oil rich in both linoleic and
α-linolenic acids. While decreases in HDL cholesterol are associated with an increase in risk of
atherosclerosis (NCEP 2002), polyunsaturated fatty acid intake typically reduces both LDL
cholesterol and HDL cholesterol without modifying the ratio of LDL : HDL (Jackson et al 1984),
a more useful measure for evaluating disease risk than LDL cholesterol or HDL cholesterol alone
(Fernandez and Webb 2008). Even though both the crude and refined raspberry seed oil (RSO)
treatments significantly lowered plasma total cholesterol and HDL cholesterol concentrations in
comparison to the coconut oil atherogenic control without affecting the non-HDL fraction of
cholesterol, an unexpected result in lieu of the ability of omega-6 fatty acids to attenuate the
downregulation of low-density lipoprotein receptor in response to excess cholesterol in HepG2
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cells (Yu-Poth et al 2005). While the lower HDL cholesterol observed with the RSO diets is
potentially a negative effect, this was observed in comparison to saturated fatty acid-enriched
coconut oil that typically increase HDL cholesterol (Kris-Etherton and Yu 1997); thus the net
effect of black raspberry seed oil intake upon plasma cholesterol metabolism may simply not
induce the HDL elevations observed with the coconut diet.
In humans, omega-3 fatty acids have demonstrated some ability to slightly increase LDL
cholesterol (Fumeron et al 1991), proposing the possibility that the mixed omega-3 and omega-6
fatty acid profile of the raspberry seed oils may attenuated the lipid modulating effects of each
other. The omega-3 fatty acid present in the raspberry seed oils, α-linolenic acid has been
demonstrated to increase LDL cholesterol levels in hamsters fed α-linolenic acid in place of oleic
acid when saturated fatty acid intake was held constant (Morise et al 2005). VLDL and LDL
cholesterol concentrations are higher in hamster with omega-3 intake in place of omega-6 intake
(Lu et al 1996). At 0.1% dietary cholesterol, plasma VLDL and LDL cholesterol concentrations
were elevated in omega-3 fed hamsters compared to omega-6 fed hamsters (Mei-Huei et al
2005), indicating that the omega-3 fatty acid LDL cholesterol increasing effect may attenuate the
omega-6 fatty acid LDL cholesterol lowering effect.
In the current study, the refined RSO elevated liver esterified cholesterol concentrations
beyond the level of accumulation observed in the coconut oil diet, an effect that was absent in the
crude RSO diet. The liver cholesterol ester accumulation in both RSOs enriched in the omega-6
fatty acid linoleic acid may have decreased acyl-coenzyme A:cholesterol acyltransferase 2
(ACAT2) expression in the liver (Lee and Carr 2004), leading to the reduction of availability of
cholesterol esters for incorporation into VLDL and subsequently reducing VLDL secretion.
While the plasma total and HDL cholesterol decreases and the accumulation of
cholesterol in the liver observed may be attributed to the effects of the specific fatty acids, the
other components of the oils (e.g., ellagic acid) that were not examined in our study may also
contributed to these effects. While the high level of phytosterols may have contributed to the
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lipid modulating effects observed, phytosterols typically lower low-density lipoprotein
cholesterol, as has been demonstrated in both humans and hamsters (AbuMweis et al 2008,
Guderian Jr et al 2007, Rasmussen et al 2006), but there was no decrease in non-HDL cholesterol.
The current mechanism accepted to explain phytosterol-induced cholesterol lowering revolves
around the displacement of micellar cholesterol with phytosterols (Jesch and Carr 2006),
subsequently increasing fecal neutral sterol excretion and decreasing cholesterol absorption
(Rasmussen et al 2006). However, there was no difference in fecal neutral sterol excretion
between the coconut oil and the RSO diets. Phytosterols were present in the diet at 0.12-0.13%
by weight of diet. While this is a low dose of phytosterols, doses as low as 0.24% of phytosterol
esters (0.08% free phytosterol equivalents) have demonstrated efficiacy in significantly lowering
non-HDL cholesterol and total cholesterol (Lin et al 2004).
In our investigation, both black raspberry seed oil dietary treatments also beneficially
lowered plasma triglyceride concentrations to the equivalent level observed in the soybean oil
diet without added cholesterol, an effect likely the result of the high level of α-linolenic acid
confirmed to be present. Omega-3 fatty acids are commonly used for their ability to consistently
attenuate elevated plasma triglyceride concentrations (Sacks and Katan 2002). While
eicosapentaenoic acid (found in fish oil) is typically used as a triglyceride-lowering therapy in
hypertriglyceridemic individuals (Lewis 2009), our study with Syrian hamsters demonstrated a
reduction in plasma and liver triglyceride concentrations with the supplementation of RSOs rich
in α-linolenic acid in comparison to a saturated fatty acid-rich coconut oil control. The raspberry
seed oils also significantly reduced liver triglycerides, indicating that RSOs may be effective
therapeutic for treatment of hypertriglyceridemia.The crude oil even lowered liver triglycerides to
the extent of the soybean diet, an effect that may be mediated by the high level of tocopherols in
comparison to the refined oil demonstrated in another study utilizing the same processing
procedure (Adhikari et al 2008).
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The oil refinement process normally does not change the triglyceride fatty acid profile of
oils to any great extent (even though it may reduce omega-3 fatty acid concentrations, overall
polyunsaturated fatty acids remain at a consistent level)(Aro et al 2000), a finding confirmed
within our study. In the case of the RSO treatment diets, the refining process did not change the
fatty acid composition of the oils; thus, any treatment differences between the two oils cannot be
attributed to the fatty acid profiles of the oils. While the oils equivalently lowered plasma and
liver triglycerides, the crude RSO diet significantly decreased liver triglycerides to the low level
of the soybean oil diet, indicating there may be some differences in lipid modulation by the oils.
Despite no significant difference in triglyceride lowering efficacy between the crude and refined
oils, cholesterol metabolism was significantly different between the two oils, reflecting the
possible effects of components of the RSOs not quantified in this study, such as ellagic acid and
tocopherols.
Our findings suggest that both refined and crude RSO effectively lowered plasma and
liver triglyceride concentrations and plasma total cholesterol but increased liver cholesterol
accumulation without decreasing plasma non-HDL, indicating both a null or potential detrimental
impact on cholesterol metabolism and a dramatic beneficial reduction of hypertriglyceridemia.
The major beneficial outcome of the RSO diets was the 46% and 29% reduction in plasma
triglycerides by the crude RSO and refined RSO diets, respectively, compared to the atherogenic
diet. Similarly, liver triglyceride concentrations in the crude and refined oil groups were
significantly reduced 46% and 36%, respectively, compared to the coconut oil diet. Even though
the refined RSO had the highest liver cholesterol accumulation, the diet also induced the greatest
fecal bile acid excretion. While RSOs did not decrease the accumulation of cholesterol esters in
the liver associated with high dietary cholesterol intake in hamsters, both crude and refined oils
deserve further investigation to determine whether the absence of a non-HDL lowering effect is
characteristic of the oil mixtures rich in linoleic and α-linolenic acid or simply an aberration of
this study. Overall, RSOs demonstrated a null effect upon cholesterol metabolism despite the
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presence of high levels of linoleic acid. However, RSOs rich in α-linolenic acid demonstrated a
beneficial dramatic hypotriglyceridemic effect regardless of processing, displaying the beneficial
decrease in triglycerides characteristic of omega-3 fatty acids (NCEP 2002).
In summary, both refined and crude black raspberry seed oils deserve a promising place
as potential therapies for the management of dyslipidemia. The triglyceride lowering effect of
black raspberry seed oil was not changed by the extent of oil processing, indicating that both oils
confer dramatically positive benefits in hamsters. Furthermore, black raspberry seed oils may
offer hypertriglyceridemic consumers an alternative to fish oil consumption to significantly lower
plasma triglycerides, as demonstrated by the hypotriglyceridemic effect of both crude and refined
oils in hamsters fed high levels of dietary cholesterol.

50

Study II.
Effect of Phytosterol Stearate Esters upon Cholesterol Metabolism in
Charles River Golden Syrian Hamsters

Cardiovascular diseases (CVD) are collectively responsible for 29% of global deaths
according to data from the World Health Organization (W.H.O. September 2009). Stroke and
coronary heart disease are two prevalent cardiovascular diseases that share the same etiology:
atherosclerotic plaque development. Individuals with elevated plasma low-density lipoprotein
cholesterol concentrations are at a higher risk for atherosclerosis (NCEP 2002).
Esterified phytosterols have demonstrated the ability to decrease serum low-density
lipoprotein cholesterol with equivalent efficacy as free phytosterols (Demonty et al 2009).
Because fatty acids have lipid-modulating effects, the esterification of free fatty acids to
phytosterols raises the possibility that the specific free fatty acid or phytosterol incorporated into
the ester may positively or negatively affect therapeutic efficacy. Phytosterols esterified to fish
oil fatty acids have demonstrated to be equally effective as sunflower oil phytosterol esters in
lowering plasma cholesterol but have the added benefit of reducing plasma triglyceride
concentrations (Demonty et al 2006), indicating that the fish oil phytosterol esters maintain the
complimentary therapeutic effects of both the fatty acid and the phytosterol (Micallef and Garg
2008). While this study demonstrated no difference in plasma cholesterol lowering efficacy
between the fish oil and sunflower oil esters, other investigations have demonstrated that the
species of fatty acid incorporated into the phytosterol ester impacts cholesterol metabolism and
the efficacy of the phytosterol ester. Phytosterols esterified to stearate-enriched fatty acid
mixtures have demonstrated an ability to decrease plasma LDL cholesterol concentrations in
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humans (Carr et al 2009) and a superior non-HDL cholesterol lowering efficacy than linoleateenriched esters in hamsters (Rasmussen et al 2006). While previous research has focused on the
impact of the fatty acid component of phytosterol esters, the effect of the specific phytosterol
species incorporated has not been fully elucidated. In the current study, we compared the lipid
lowering efficacy of three different phytosterols when incorporated into phytosterol stearate
esters: stigmasterol, sitosterol, and sitostanol.
Stearic acid has demonstrated a neutral or cholesterol-lowering effect upon plasma lowdensity lipoprotein cholesterol concentrations whereas other saturated fatty acids have
demonstrated hypercholesterolemic effects (Grundy 1994). Previous work in our laboratory has
shown that stearic acid may even lower total cholesterol in comparison to palmitic, oleic, elaidic,
and linoleic acids when co-administered in hamsters fed a 0.05% cholesterol diet (Schneider et al
2000). While this effect may disappear when dietary cholesterol intake increases (Imaizumi et al
1993), there does appear to be an increase in fecal neutral excretion upon increased dietary stearic
acid intake (Schneider et al 2000). Stearate-enriched phytosterol esters have a dose-dependent
response in non-HDL cholesterol lowering efficacy and a synergistic effect as evidenced by their
increased efficacy in comparison to stearic acid and free phytosterols in combination (Guderian Jr
et al 2007). Subsequently, we utilized phytosterol stearate esters in our investigation into the
effect of the phytosterol species upon therapeutic effectiveness.
In order to determine the most efficacious phytosterol stearate combination with a
feasible number of animals and treatment groups, we focused our attention upon sitosterol,
stigmasterol, and sitostanol. Sitosterol, campesterol and stigmasterol are the most abundant plant
sterols in nature, and the most readily available for incorporation into phytsterol esters
(Lichtenstein and Deckelbaum 2001). However, campesterol is expensive and was deemed
impractical both for our study and probably for the most cost-effective atherosclerotic risk
reduction with phytosterol esters. Furthermore, some research has indicated that campesterol
(9.6%) and campestanol (12.5%) is more highly absorbed than stigmasterol (4.8%) or sitosterol
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(4.2%) (Jain et al 2008, Lutjohann et al 1995), presenting a potentially increased risk of negative
effects of campesterol/campestanol phytosterol esters, as the accumulation of phytosterols may
increase risk for atherosclerosis (Weingärtner et al 2009). Other more reliable methods have
reported values as low as 0.04% for sitostanol and 1.9% for campesterol absorption (Ostlund et al
2002a). While there is little data supporting the hypothesis that serum phytosterols independently
increase disease risk, campesterol was excluded from the current investigation and sitosterol,
stigmasterol, and sitostanol were chosen for examination.
Our investigation included an atherogenic basal diet high in both cholesterol (0.12% g/g)
and saturated fatty acid-enriched coconut oil with the addition of individual phytosterol stearates
(2.5% g/g) within the treatment diets in place of cornstarch in the control. The three phytosterol
stearate treatment diets consisted of sitosterol stearate, stigmasterol stearate, or sitostanol,
allowing us to examine the effect of the specifc phytosterol incorporated into the phytosterol
stearate esters upon cholesterol lowering efficacy.
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Materials and Methods

Experimental Animals and Diets. Thirty-nine male Syrian hamsters (Charles River Labs,
Wilmington, MA) with body masses ranging from 56g to 70g were divided into experimental
groups of 9-10 hamsters and separated into individual polycarbonate cages with a sawdust
bedding. The hamsters were fed ad libitum for twenty-eight days and maintained in a humiditycontrolled 25°C room with a twelve hour light/dark cycle. The hamsters were fed a semi-purified,
atherogenic AIN-93M diet high in cholesterol (0.12% g/g) and coconut oil (8% g/g) (Table 1)
(Reeves et al 1993). Hamsters fed a high cholesterol (0.1 g/100g) and saturated fat (10 g/100g)
diet respond similarly to humans to dietary interventions and develop comparative pathologies,
making the hamster an appropriate model for studies investigating atherosclerosis (Dorfman et al
2003). Treatment diets consisted of the replacement of cornstarch in the control diet with one of
the following individual phytosterol stearates at 2.5% (g/g): stigmasterol stearate, sitosterol
stearate, or sitostanol stearate (sitostanol is structurally equivalent to stigmastanol; Figure 1). The
composition and purity of the administered phytosterol stearates was determined in triplicate
using GC analysis after ester saponification, yielding purity values of 96.8%  2.7% for sitostanol
stearate, 98.5%  0.2% for stigmasterol stearate, and 76.3%  1.3% for sitosterol stearate (Table
3). The phytosterol stearates were synthesized from free phytosterols and stearoyl chloride
purchased from TCI America (Portland, OR, USA) in the laboratory of Dr. Patrick Dussault
(Department of Chemistry, University of Nebraska). The diets were prepared within our
laboratory utilizing manual mixing and least-to-greatest addition order to maximize nutrient
distribution. Diets were stored in 1 kg portions at -80°C. At the beginning of week four, a second
batch of diets was made for the animals and the remaining amount of diet was divided equally
among the hamsters to ensure adequate food availability until the diets were complete. The AIN-
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93 mineral and vitamin mixes, casein, dextrinized cornstarch, and fibers were purchased from
Dyets, Inc. (Bethlehem, PA). Choline bitartrate, L-cystine, and cholesterol were purchased from
Sigma Chemicals (St. Louis, MO). Cornstarch, sucrose, and soybean oil were purchased from a
local grocery store. All procedures were approved by the Institutional Animal Care and Use
Committee of the University of Nebraska.
Hamster feed intake and body weight records were maintained weekly. During week
three, fecal matter was collected for four days after dual-isotope dose administration in soybean
oil for the measurement of cholesterol absorption. Radio-labeled [14C]cholesterol and
[3H]sitostanol were purchased from American Radiolabeled Chemicals (St. Louis, MO) with
cholesterol 14C labeled at the 4th carbon and sitostanol labeled with tritum atoms bound to the the
5th and 6th carbon within the steroid ring of sitostanol to prevent metabolic catabolism. Bedding
was collected for seven-day fecal pellet recovery and sterol excretion analysis at the end of week
four.
On day twenty-eight, hamsters were euthanized with carbon dioxide, the thoracic cavity
was exposed via incision, and blood was collected by cardiac puncture using 10 mL syringes
prior to transfer to 10 mg EDTA containing tubes on ice. Plasma was isolated by centrifugation at
1000 x g for 30 minutes at 4°C, and the separated upper-phase was collected and stored on ice at
4°C for three days prior to storage at -80°C until analyzed. Whole livers were excised, weighed,
and snap-frozen in liquid nitrogen prior to storage at -80°C.
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Table 1. Diet composition
Control

Sitostanol
Stearate

Stigmasterol
Stearate

Sitosterol
Stearate

g/kg
Cornstarch

404.5

379.5

379.5

379.5

Dextrinized cornstarch

155.0

155.0

155.0

155.0

Casein

140.0

140.0

140.0

140.0

Sucrose

100.0

100.0

100.0

100.0

Coconut oil

80.0

80.0

80.0

80.0

Soybean oil

20.0

20.0

20.0

20.0

Sitostanol stearate1

---

25.0

---

---

Stigmasterol stearate

---

---

25.0

---

Sitosterol Stearate

---

---

---

25.0

Insoluble fiber (cellulose)

40.0

40.0

40.0

40.0

Soluble fiber (guar gum)

10.0

10.0

10.0

10.0

1.2

1.2

1.2

1.2

AIN-93 mineral mix

35.0

35.0

35.0

35.0

AIN-93 vitamin mix

10.0

10.0

10.0

10.0

L-Cystine

1.8

1.8

1.8

1.8

Choline bitartrate

2.5

2.5

2.5

2.5

Cholesterol
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Table 2. Diet macronutrient composition
Control

Sitostanol
Stearate

Stigmasterol
Stearate

Sitosterol
Stearate

g/kg
Carbohydrate

693.8

668.8

668.8

668.8

Protein

140.0

140.0

140.0

140.0

Fat

100.0

100.0

100.0

100.0

kcal/kg
Carbohydrate

2775.2

2675.2

2675.2

2675.2

Protein

560.0

560.0

560.0

560.0

Fat

900.0

900.0

900.0

900.0

4235.2

4135.2

4135.2

4135.2

Total

%energy
Carbohydrate

65.5

64.7

64.7

64.7

Protein

13.2

13.5

13.5

13.5

Fat

21.3

21.8

21.8

21.8
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A. Sitosterol

B. Stigmasterol

C. Sitostanol

D. Stearic Acid
Figure 1. Chemical structures

Table 3. Phytosterol stearate treatment purity and composition
Phytosterol

Sitostanol
Stearate

Stigmasterol Stearate

Sitosterol Stearate

%
Campesterol

1.6  1.4b

0.1  0.2b

9.5  0.3a

Stigmasterol

1.5  1.3b

98.5  0.2a

0.2  0.3b

Sitosterol

0.0  0.0b

1.0  0.5b

76.3  1.3a

Sitostanol

96.8  2.7a

0.4  0.5c

14.0  1.2b

Treatment Purity1

96.8  2.7a

98.5  0.2a

76.3  1.3b

Values are means ± S.D., n = 3.
1
Treatment purity denotes the percentage of the treatment phytosterol within the mixture.
a,b
Means within a row having different superscripts are statistically different (P < 0.05).
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Dual-Isotope Cholesterol Absorption Assay. Cholesterol absorption was quantified via
the dual-isotope [14C]cholesterol and [3H]sitostanol disintegrations per minute (dpm) ratio method
previously published by Turley et al. (Turley et al 1994) and modified by our laboratory (Cai and
Carr 1999, Schneider et al 2000). During week three on day fourteen, a 30 µL dose of ~20 µL of
0.1 mCi/mL [14C]cholesterol and 1 µL of 0.706 mCi/mL decay-adjusted [3H]sitostanol in 2.4 mL
of soybean oil was administered to each animal via gavage, and animals were switched to cages
with new bedding to prevent contamination of fecal collection.
On day fifteen, the hamsters were again dosed with 25 µL. The bedding was collected on
day eighteen, and the radioactive fecal pellets isolated with forceps. Three aliquots of the dualisotope soybean dose were saved in 4 mL of Bio-Safe II cocktail (Research Products
International) along with a Bio-Safe II blank to allow for quantification.Approximately 2 g of
fecal pellets was placed into glass 20 x 150 tubes. After the addition of 95% ethanol (9 mL) and
50% KOH in water (1 mL), the samples were vortexed before overnight hot extraction at 80°C
overnight. The extraction was halted with 3 mL of deionized water. After vortexing, hexane was
added (7 mL), the samples were mixed by shaking and left overnight to allow for phase
separation. The upper hexane layer was transferred to 7 mL scintillation vials directly. The
scintillation vials were allowed to dry under exposure to Ultra Violet light over five days to
breakdown chromophore compounds that could potential interfer with scintillation cocktail light
propagation. BioSafe II scintillation cocktail (4 mL) was added to each sample and both the
samples and the dose vials were read after vortexing using a dual-gated 14C and 3H procedure,
yielding a istope dose cholesterol-to-sitostanol ratio of 1.159 which was used to calculate animal
cholesterol absorption from the following formula:

Percent Cholesterol
Absorption

( [14C]dose/[3H]dose - [14C]feces/[3H]feces )
=

([14C]dose/[3H]dose)

x 100 %
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Quantification of Plasma Lipids. Plasma total cholesterol was measured colorimetrically
in 96-well plates using reagents as previously described (Carr et al 1993). The HDL fraction
cholesterol quantification was performed using the total cholesterol assay after precipitation of
apolipoprotein-B containing lipoproteins (VLDL and LDL) with a 1:1 dilution with HDL
Precipitating Reagent (Thermo Electron Corp., Melbourne, Australia) and subsequent
centrifugation at >1000 x g for 10 minutes to isolate the HDL lipoprotein fraction from whole
plasma for analysis. Non-HDL cholesterol was calculated as the difference between total
cholesterol and HDL cholesterol.
Quantification of Liver Lipids. Recording the exact weight, about 0.5g of each frozen
liver sample was minced, and the lipids were extracted using the Folch extraction procedure
(Folch et al 1957). After the addition of 5 mL chloroform/methanol (2:1, v/v) samples were
flushed with nitrogen and extracted over the weekend and by heat for five hours at 50°C before
filtrationg using Whatman #41 filter paper into 15 mL graduated conical glass tubes. The
extraction tube and funnel were each washed three times with excess chloroform/methanol (2:1)
to maintain quantitative technique, and the volume of each extract was brought to 10 mL prior to
the additional of 2 mL of 0.88% KCL, vortexing, and phase separation by brief centrifugation.
The lower phase volume was recorded, the upper phase was aspirated, and the lower phase was
transferred to a clean tube, flushed with nitrogen, and stored at 4°C.
Triton X-100 (10% chloroform (v/v); 0.4 mL) was added to aliquots (0.5-0.1 mL) of the
liver lipid extracts to maintain solubilization of the lipids upon the addition of 0.96 mL of
deionized H2O for aqueous enzymatic analysis as previously described (Carr et al 1993). Aliquot
total cholesterol, free cholesterol, phospholipids, and triglycerides were quantified in duplicate.
Total cholesterol and triglycerides were measured using the reagents used by Carr et al. obtained
from Roche Diagnostics (Indianapolis, IN), whereas the free cholesterol and phospholipid
reagents were purchased from Wako Chemicals (Richmond, VA). Liver esterified cholesterol was
quantified as the difference between total and free cholesterol.

60
Quantification of Fecal Bile Acids. Bile acids were quantitatively extracted from
approximately 100 mg of ground fecal matter, the exact mass was recorded, and the lipids
extracted via the Folch procedure using 10 mL of chloroform/methanol (2:1, v/v) (Folch et al
1957) after the addition of 0.7 mL of 0.5 M HCl to maximize extraction efficiency. Samples were
flushed with nitrogen, vortexed, and left at room temperature for extraction overnight prior to the
addition of 2 mL of 0.88% KCl and phase separation via centrifugation at 1000 x g for 10
minutes. The upper phase was transferred to a graduated conical tube, and the lower phase was
washed with 3 mL of chloroform/methanol/water (3:48:47, v/v), inverted six times, centrifuged
for minutes at 1000 x g, and the upper phase added to the first upper phase. The total volume of
the collected bile acid containing phases was recorded, and the upper phase was transferred to a
new tube, flushed with nitrogen, and stored at 4°C until analysis.
Total bile acids were quantified using 3-hydroxysteroid dehydrogenase (Sheltawy and
Losowsky 1975). Aliquots (2 mL) of the upper phase were evaporated at ~50°C under nitrogen in
standardized glass cuvets and re-solubilized in 100 µL of methanol prior to the addition of 3.5 mL
of -NAD in pH-adjusted CAPS buffer (0.2 mg/mL; pH 10.8) to each sample and subsequent
measurement of background absorbance at 340 nm. After the addition of 0.4 mL of 3hydroxysteroid dehydrogenase (0.75 units/mL of 0.01 M phosphate buffer, pH 7.2), samples were
incubated at 37C for thirty minutes, and the absorbance was read at 340 nm. After adjusting for
the difference in volume between the background and post-incubation absorbances measured, the
difference in absorbance was used to quantify the total bile acids present in the fecal samples
utilizing a 0.01 M cholic acid standard curve diluted to the range of 0.1-0.5 mmol/assay and
allowing for accurate quantification. -NAD, CAPS, cholic acid, and 3-hydroxysteroid
dehydrogenase were all purchased from Sigma-Aldrich (St. Louis, MO, USA).
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Free and Esterified Sterol Quantification. Fecal sterols were extracted from
approximately 30 mg of ground fecal matter (exact weight recorded), using the Folch procedure
(Folch et al 1957) and free sterols were measurd via direct GC analysis whereas esterified sterols
were quantified using a modification of the thin-layer chromatography (TLC) protocol published
by Nissinen et al. (Nissinen et al 2007) after the addition of 0.1 mL of 300 µg of 5α-cholestane
(esterified sterol internal standard) and 300µg of lanosterol (free sterol internal standard). While
Nissinen et al. (2007) utilized epicoprostanol as the free sterol fraction internal standard in
analyzing human proximal jejunum samples, this was not deemed suitable for our fecal matter
analysis because epicoprostanol (5β-Cholestan-3α-ol) is a stereoisomer of dihydrocholesterol (5αCholestan-3β-ol), a major metabolite of microfloral cholesterol modification commonly
quantified in hamster fecal samples and incomplete separation of the two compounds was
forecasted; thus lanosterol, which was not even detected in hamster fecal samples by Lee et al.
(Lee et al 2005), was used. The lanosterol available was ~51% pure but demonstrated two
prominent peaks upon GC analysis (n = 4) accounting for 35.83% ± 0.20% (P1) and 33.30% ±
0.21% of the observed peak area with an elution pattern that did not overlap with sterol peaks of
interest (data not shown). Unfortunately, this purity test was only available after lanosterol
addition to samples. Lanosterol proved to be an unreliable marker of free sterol migration during
TLC analysis in our mobile phase (data not shown); subsequently, free sterol concentrations of
the samples were analyzed via direct GC analysis.
After the addition of the internal standards to the fecal samples weighed into 15 mL
conical graduated glass tubes, 0.2 mL of 0.5 M HCl and 5 mL of chloroform/methanol (2:1, v/v)
were added to extract fecal lipids using the Folch protocol (Folch et al 1957). Samples were
flushed with nitrogen, vortexed, and left at room temperature for extraction for one hour,
vortexing every thirty minutes prior to the addition of 1 mL of 0.88% KCl (wt/v), inversion of the
samples to ensuring mixing (six times), and centrifugation at 1000 x g for twenty minutes to
induce phase separation. The lower phase volume was recorded, the upper phase was aspirated
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and discarded, and the lower phase was carefully decanted into a new glass tubes to remove fecal
debris before being flushed with nitrogen and storedat 4°C until TLC analysis (esterified sterols)
or direct GC quantification (free sterols).
Because previous tests running the fecal samples on TLC plates demonstrated improper
separation presumed to be caused by the high concentration of free and/or esterified phytosterols
in the samples, only ~5 mg of each fecal sample was applied to the plate in a 1 inch band as
determined to be the upper limit of reliable lipid separation of the current fecal samples (data not
shown). In order to fall beneath this 5 mg of total lipid TLC lane mass application limit, previous
testing data were used to estimate the appropriate aliquote volume to be 0.7 mL; thus 0.7 mL of
each lower phase was transferred to a new tube, dried under nitrogen at 50°C, and transferred to a
1 inch-wide TLC plate lane twice with 50 µL of chloroform after gentle vortexed each time..
Each Whatman AL-SIL G TLC plate (Aluminum-Backed, 60Å Silica, 250 µm x 20 x 20 cm;
Catalog # 4420-221) contained a standard lane containing phytosterol esters and free
phytosterols.
The mobile phase consisted of 50 mL of heptane/ethyl ether (50:50, v/v) as described
previously for separation of free and esterified sterols (Nissinen et al 2002), and it was changed
after every two plates with fifteen minutes allowed prior to each run for mobile phase chamber
equilibration. The plates were run for forty-five minutes, removed from the chamber, and
allowed to dry for at least fifteen minutes. The standard lane was carefully liberated from the
plate with a razor blade and developed in an iodine chamber to provide visual confirmation of
separation of the the free and esterified sterol fractions before standardized cutting of all of the
free and esterified fractions based upon the standard lane of each sample plate. The esterified
fractions were cut from the plate, carefully folded to prevent silica-bound sample loss via plate
flaking, and placed into clean individual glass tubes. The fractions were distributed in such a
manner that left a mid-section between the esterified and free sterol fractions, leaving a
possibility of sample loss upon incomplete separation. Analysis of six of the samples in this

63
region demonstrated that despite the possibility of the introduction of error, there was subjectively
minimal presence of peaks in the TLC plate region. Chloroform was added to each tube in excess
of that required to cover the aluminum-backed folded TLC plate fractions. Samples were flushed
with nitrogen and stored at 4°C for less than one week.
The esterified sterol fractions were shaken for ten seconds and then centrifuged at 1000 x
g for twenty minutes to pellet the silica at the bottom of the tube prior to decantation into new
tubes. To maximize recovery, the TLC plate extraction was repeated with another excess of
chloroform. The collected chloroform fractions were flushed with nitrogen, vortexed and shaken,
and centrigued for twenty minutes at 1000 x g. The esterified, mid-section, and free sterol TLC
extracts in chloroform were all dried under nitrogen at 50°C, utilizing excess chloroform to wash
down the sides and concentrate the samples at the bottom. The esterified fractions were
saponified by 1 ml of 1 M KOH in methanol prior to leaving the nitrogen-flushed samples
overnight at room temperature and several periods of 60- 80°C of heat and frequent vortexing to
ensure complete saponification. Distilled water (1 mL) was added, the samples vortexed, and
hexane (2 mL) was added to extract non-saponifiables. The samples were mixed using a multimixer set on high for five minutes, using haphazard grouping prior to phase separation via
centrifugation for five minutes at 1000 x g and the transfer of upper hexane phases to new tubes.
The extraction was repeated with an additional 2 mL of hexane to maximize recovery.
The esterified samples and a separate 0.7 mL aliquot of the same fecal lipid extracts
utilized for the esterified analysis were then dried under nitrogen at 50°C. Following the addition
of 100 µL of hexanes to the dried fecal samples and gentle vortexing, the dried samples were
twice transferred to GC vials equipped with 300 µL inserts, yielding a final volume of 200 µL.
All GC analyses were performed on an AT-5 capillary column (Alltech, Deerfield, IL) with
helium as the carrier gas. The temperature program utilized a 15.0°C/minute temperature ramp
from an initial one minute hold at 270°C to a final hold at 300°C of fourteen minutes, an inlet
temp of 270°C, and a flame ionizing detector temperature of 300°C.

64
Statistical Analysis. Statistical One-way ANOVA analyses were performed using the
GLM procedure (version 9.0; SAS Institute, Cary, NC, USA) and the simulated adjustment for
multiple comparisons using the ―/pdiff‖ option of ―lsmeans‖ in SAS. The simulated adjustment
was used instead of the Tukey to account for the different number of experimental units within
each treatment group (control, n=9; phytosterol stearate treatments, n=10). The standard error of
the mean was used to represent mean treatment variations displayed in both tables and figures
with the exception of the phytosterol treatment purity, which used the standard deviation. The
coefficient of variation was calculated for many of the assays via sample replicates (n=3-5) in
order to quantifying the extent of intra-assay variation for the protocols (Table 4). Correlation
analysis was calculated using the ―PROC CORR‖ command in SAS (version 9.0; SAS Institute,
Cary, NC, USA).
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Table 4. Intra-assay variation: coefficient of variation for liver and fecal assays
Intra-Assay
Replicates

Coefficient of Variation1

n

%

Total Cholesterol

3

3.40%

Free Cholesterol

3

0.53%

Esterified Cholesterol

3

5.49%

Triglycerides

3

8.00%

Phospholipids

3

2.17%

Free Neutral Sterols

5

5.12%

Esterified Neutral Sterols

5

25.61%

Total Neutral Sterols

5

9.52%

Free Phytosterols

5

23.38%

Esterified Phytosterols

5

19.12%

Total Phytosterols

5

17.54%

Total Sterols

5

18.74%

Free Phytosterol Treatment

5

10.33%

Esterified Phytosterol Treatment

5

23.93%

Total Phytosterol Treatment

5

22.35%

Phytosterol Treatment FS/Total2

5

34.30%

Phytosterol Treatment ES/Total3

5

1.92%

Bile Acids

3

16.1%

Quantitative Assay

Liver

Fecal

Coefficient of variation (CV) calculated by dividing the standard deviation (σ) by the mean (μ).
FS/Total = phytosterol treatment free sterols divided by phytosterol treatment total sterols.
3
ES/Total = phytosterol treatment esterified sterols divided by phytosterol treatment total sterols.
1
2
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Results

Body Weights, Food Intake, and Cholesterol absorption. Weekly hamster body weights
(Table 5) and cumulative body weight gain (Figure 2) did not significantly differ (P>0.05)
between diets during any of the study period weeks. Food intake measurements obtained weekly
did not differ among the treatments for week one, week two, or week three (P>0.05). During
week four, the dietary treatments had significantly different food intakes (Table 6). The control
group dietary intake during week four was significantly greater than both the stanol stearate and
stigmasterol stearate treatment groups but not the sitosterol stearate group. None of the
phytosterol stearate treatments differed significantly in food intake during week four (P>0.05).
Despite the significantly different feed intakes among the treatment groups, the average weekly
intakes over the entire study did not statistically differ. Because of the difference in dietary feed
intakes, the dietary intake data were fractionated to display the dietary intake of phytosterols and
cholesterol based upon the dietary composition (Table 7). The dietary intake of phytosterols
during week one, week two, and week three were statistically equivalent among the three
phytosterol stearate treatments and differed from the control by design. During week four of the
study, the dietary intake of sitosterol stearate was significantly higher than stigmasterol stearate
but not sitostanol stearate. The stigmasterol stearate and stanol stearate treatment dietary
phytosterol treatment intakes did not statistically differ (P>0.05). The average weekly dietary
intake of the phytosterol stearate treatments did not differ during the study. Because the total
treatment phytosterol fecal excretion did not differ statistically across the groups, the differences
in treatment phytosterol intakes during week four were accepted as potential confounding
variables within the current study without further consideration. The cholesterol dietary intakes
only differed statistically during week four of the study, an effect that was not present when
examining the average weekly dietary cholesterol intake. During week four, dietary intake of
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cholesterol was highest in the control but did not differ statistically from the sitosterol stearate
treatment group. The sitostanol stearate and stigmasterol stearate dietary cholesterol intakes were
statistically lower than the control diet, but there was no statistical difference between any of the
phytosterol stearate treatments. Despite no statistical difference in the average weekly cholesterol
intake across the diets, cholester intake was also considered a potential confounding variable of
the current study. Cholesterol absorption percentages ranged from 59.9% ± 3.0% (sitostanol
stearate) to 66.2% ± 3.0% (sitosterol stearate) but did not differ significantly among the
phytosterol stearate treatment groups or even in comparison to the control, indicating that the
differences in intakes of phytosterol stearates and cholesterol did not result in any difference in
the extent of intestinal absorption but may have confounded any treatment differences (Table 7).
Plasma Cholesterol. Plasma total cholesterol concentrations were unchanged by any of
the treatments in comparison to the control (P>0.05) after four weeks on the diets (Table 8). The
plasma total cholesterol concencentrations of the control (6.14  0.23 mmol/L), sitostanol stearate
(5.67  0.34 mmol/L), stigmasterol stearate (5.87  0.21 mmol/L), and sitosterol stearate (5.42 
0.26 mmol/L) were statistically equivalent. The non-HDL cholesterol concentrations of the
control, sitostanol stearate, stigmasterol stearate, and sitosterol stearate groups were 3.83  0.14
mmol/L, 3.45  0.27 mmol/L, 3.50  0.16 mmol/L, and 3.33  0.17 mmol/L, respectively.
However, the non-HDL cholesterol fractions did not significantly differ among any of the groups
(P>0.05). As expected, the HDL cholesterol concentrations of the treatment groups did not
significant differ, ranging from 2.09  0.10 mmol/L (sitosterol stearate) to 2.36  0.10 mmol/L
(stigmasterol stearate).
Liver Cholesterol, Triglycerides, and Phospholipids. Liver total cholesterol
concentrations were statistically similar across the four diets, ranging from 13.7  1.8 µmol/g in
the sitostanol stearate treatment group to 18.9 ± 2.1 µmol/g in the stigmasterol stearate treatment
(Table 9). Free cholesterol liver concentrations significantly differed in response to the different
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diets after weeks upon treatment (Table 9). The free cholesterol concentrations in the liver were
highest and statistically equivalent in the control group (4.7 ± 0.1 µmol/g) and the stigmasterol
stearate groups (4.5 ± 0.0 µmol/g). Both the control and the stigmasterol stearate treatment group
had statistically elevated concentrations of free cholesterol in comparison to both the sitostanol
stearate and sitosterol stearate treatments, which were statistically equivalent with respective
means of 4.2 ± 0.1 µmol/g and 4.2 ± 0.1 µmol/g. The calculated esterified cholesterol
concentration means were unaffected by phytosterol treatment and no difference between any of
the dietary groups was observed (P>0.05). Neither the liver triglyceride nor the phospholipid
concentrations statistically differed across the dietary treatment groups. The whole liver weights
expressed as g x 100 g-1 of body weight did not significantly differ among the diets.
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Table 5. Hamster body weight
Control

Sitostanol
Stearate

Stigmasterol
Stearate

Sitosterol
Stearate

g
Week 0

61.4  0.7

62.4  1.0

64.5  0.9

61.5  1.1

Week 1

79.0  2.4

79.7  2.1

83.9  2.2

78.5  2.6

Week 2

95.2  3.5

98.2  2.1

103.3  2.2

96.5  3.6

Week 3

109.6  2.9

109.6  2.5

115.1  2.6

109.3  3.3

Week 4

117.4  2.7

116.9  2.8

120.7  3.1

118.1  2.7

Values are means  SEM, n = 9-10. No treatment differences were detected using One-way
Anova analysis with pdiff simulated comparisons (P>0.05).

Cumulative Body Weight Gain (g)

70.0
60.0
50.0
40.0

Control

30.0

Sitostanol
Stigmasterol

20.0

Sitosterol
10.0
0.0
0

1

2

3

4

Study Period (weeks)

Figure 2. Cumulative body weight gain in hamsters during phytosterol stearate dietary treatment
study. No treatment differences were detected using One-way Anova analysis with pdiff
simulated comparisons (P>0.05).
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Table 6. Food intake
Control

Sitostanol
Stearate

Stigmasterol
Stearate

Sitosterol
Stearate

g/day
Week 1

8.2  0.5

8.7  0.7

9.4  1.0

8.0  0.4

Week 2

12.0  0.9

11.5  1.0

10.9  0.5

11.1  0.7

Week 3

11.3  0.6

12.2  0.7

13.2  0.4

12.2  0.4

Week 4

7.5  0.8a

4.2  0.5b

3.2  0.6b

5.3  0.4a,b

Average

9.7  0.6

9.2  0.6

9.2  0.5

9.2 0.3

Values are means  SEM, n = 9-10.
a,b
Means within a row having different superscripts are statistically different (P < 0.05).
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Table 7. Dietary sterol intake1 and cholesterol absorption
Control

Sitostanol
Stearate

Stigmasterol
Stearate

Sitosterol
Stearate

mg/day
Phytosterols
Week 1

0  0b

218  17a

234  25a

200  11a

Week 2

0  0b

289  24a

274  12a

277  17a

Week 3

0  0b

305  16a

331  10a

305  10a

Week 4

0  0c

106  14a,b

80  16b

133  10a

Average

0  0b

230  16a

230  13a

229  8a

Week 1

9.8  0.6

10.5  0.8

11.2  1.2

9.6  0.5

Week 2

14.4  1.1

13.9  1.2

13.1  0.6

13.3  0.8

Week 3

13.5  0.7

14.7  0.8

15.9  0.5

14.6  0.5

Week 4

9.0  1.0a

5.1  0.7b

3.8  0.8b

6.4  0.5a,b

Average

11.7  0.7

11.0  0.8

11.0  0.6

11.0  0.4

63.0  2.0

66.2  3.0

Cholesterol

%
Cholesterol Absorption
1

61.6  3.0

59.9  3.0

Dietary phytosterols supplemented at 2.5% dosage (g/kg) in addition to basal phytosterol intakes
for the phytosterol stearate treatments. Dietary cholesterol supplemented at 0.12% dosage (g/kg)
in all diets. These percentages were used to calculate the sterol intake based upon total food
intake during each week.
a,b,c
Means within a row having different superscripts are statistically different (P < 0.05).
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Table 8. Plasma lipid concentrations
Control

Sitostanol
Stearate

Stigmasterol
Stearate

Sitosterol
Stearate

mmol/L
Total cholesterol

6.14  0.23

5.67  0.34

5.87  0.21

5.42  0.26

non-HDL cholesterol

3.83  0.14

3.45  0.27

3.50  0.16

3.33  0.17

HDL cholesterol

2.31  0.17

2.21  0.10

2.36  0.10

2.09  0.10

Values are means  SEM, n = 9-10. No treatment differences were detected using One-way
Anova analysis with simulated comparisons (P>0.05).

Table 9. Liver weight and lipid concentrations
Control

Sitostanol
Stearate

Stigmasterol
Stearate

Sitosterol
Stearate

µmol/g
Total cholesterol

17.8  2.1

13.7  1.8

18.9  2.1

15.8  2.2

Free cholesterol

4.7  0.1a

4.2  0.1b

4.5  0.0a

4.2  0.1b

Esterified cholesterol

13.1  2.1

9.5  1.8

14.4  2.0

11.5  2.2

Triglyceride

5.0  0.3

5.4  0.4

4.6  0.3

5.6  0.4

Phospholipid

13.1  0.3

12.6  0.3

12.8  0.3

12.5  0.3

g/100 g of body weight
Liver

5.99  0.13

5.97  0.17

5.73  0.14

5.92  0.10

Values are means  SEM, n = 9-10.
a,b
Means within a row having different superscripts are statistically different (P < 0.05).
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Fecal Free and Esterified Neutral Sterols. While neutral free sterol excretion was
statistically equivalent across the four dietary groups (P>0.05), esterified and total neutral sterol
excretion were significantly different among the treatments (Table 10). The sitosterol stearate
supplemented diet resulted in an increase in fecal esterified neutral sterols significantly greater
than the other phytosterol esters or the control. Conversely, the control, sitostanol stearate, and
stigmasterol stearate diets demonstrated statistically equivalent esterified neutral sterol excretion.
Total neutral sterol excretion was significantly higher in the sitosterol stearate group than either
the control or the stigmasterol stearate treatment but did not differ statistically from the sitostanol
stearate treatment; however, the p-value of the comparison of the total neutral sterol excretion in
the sitosterol stearate and sitostanol stearate dietary groups approached significance (P=0.0556).
The control, sitostanol stearate, and stigmasterol stearate groups were statistically equivalent
(P>0.05). The percent esterified neutral sterol excretion was significantly the highest in the
sitosterol stearate dietary group (37.78% ± 3.78%), whereas the stigmasterol stearate (11.29% ±
0.58%) and sitostanol stearate (4.07% ± 0.55%) treatments did not significantly differ despite the
presence of a significantly higher percent esterified neutral sterol excretion in the stigmasterol
stearate treatment versus the control (1.81% ± 0.40%) (Table 10).
Fecal Free and Esterified Phytosterols and Total Sterols. Free phytosterol fecal
excretion was equivalent and significantly higher in both the stigmasterol stearate and the
sitosterol stearate treatments than the statistically equivalent control and sitostanol stearate groups
(Table 10). Esterified phyosterol fecal excretion did not differ among the treatment groups but
was significantly lower in the control group versus the phytosterol stearate diets. The total
phytosterol excretion in the phytosterol stearates was statistically equivalent and greater than the
control diet, reflecting the intended study design. The total sterol fecal excretion demonstrated an
identical pattern with phytosterol treatment diets resulting in significantly higher amounts of total
sterol excretion than the control (P<0.05).

74
While the absence of a significant effect on fecal neutral sterol excretion in response to
sitostanol stearate and stigmasterol stearate treatments in comparison to the control may simply
be due to a mirrored significantly different phytosterol stearate treatment intake during week four
(fecal sterol measurements were quantified for week four), the presence of statistically equivalent
fecal total phytosterol excretion levels indicate that the calculated difference in intake may not
have manifested itself across the treatment groups to any statistically significant extent.
Subsequently, data were analyzed disregarding the calculated difference in phytosterol stearate
treatment intake during week four with the acknowledgement that the variable may confound our
conclusions.
Free and Esterified Phytosterol Stearate Treatment Excretion. Free phytosterol
treatment excretion was significantly higher in the sitosterol stearate treatment group than
sitostanol stearate but not stigmasterol stearate (Table 10). Esterified phytosterol stearates
differed significantly in that the sitostanol stearate treatment had a significantly higher excretion
than either the stigmasterol stearate or the sitosterol stearate treatments, which were statistically
equivalent. Total phytosterol treatment excretion among the phytosterol stearate diets was
significantly higher in the sitostanol stearate group than both the stigmasterol stearate and
sitosterol stearate treatments, which did not differ significantly. The percent of free treatment
phytosterol excretion to total treatment phytosterol sterol excretion was significantly higher in the
sitosterol stearate dietary treatment (4.68% ± 0.90%) in comparison to the statistically equivalent
sitostanol stearate (0.88% ± 0.22%) and stigmasterol stearate diets (2.45% ± 0.31%), indicating
the level of net hydrolysis of the phytosterol treatments. The percent free phytosterol treatment
fecal excretion mirrored the percent esterified neutral sterol excretion, demonstrating a significant
correlation in a post-hoc statistical analysis (r = 0.6304, p = <0.0001; Figure 3).
Fecal Bile Acid Excretion and Fecal Output. The bile acid excretion did not differ
significantly among any of the diet groups (Table 11). The fecal output was significantly higher
in the sitostanol stearate and sitosterol stearate treatments than in the control but not in the
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stigmasterol stearate treatment, which did not differ statistically from any of the diets (Table 11).
This fecal output may simply reflect the significant difference in food intake observed during
week 4 or it may be the result of treatment effects upon fecal excretion transit time. The effect
will not be considered further in this study.
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Table 10. Fecal sterol excretion
Control

Sitostanol
Stearate

Stigmasterol
Stearate

Sitosterol
Stearate

µmol x day–1 × 100 g–1 body weight
Neutral sterols1
Free

6.02  0.32

7.39  0.62

6.41  0.37

6.07  0.54

Esterified

0.11  0.02b

0.31  0.05b

0.84  0.09b

3.74  0.45a

Total

6.12  0.31b

7.70  0.64a,b

7.24  0.46b

9.80  0.72a

%
Esterified/Total

1.81 ± 0.40c

4.07 ± 0.55b,c

11.29 ± 0.58b

37.76 ± 3.78a

µmol x day–1 × 100 g–1 body weight
Phytosterols2
Free

1.90  0.21b

Esterified
Total
Total Sterols3

2.31  0.39b

4.47  0.48a

4.73  0.72a

0.05  0.01b 129.74  7.55a

100.71  6.38a

125.59  14.91a

1.95  0.21b 132.05  7.55a

105.18  6.59a

130.32  14.97a

8.07 + 0.44b 139.75 + 8.01a

112.42 + 6.86a

140.13 + 15.46a

Phytosterol Treatment4
Free

N/A

1.13  0.27b

2.30  0.32a,b

3.51  0.48a

Esterified

N/A

129.74  7.55a

91.48  6.03b

85.97  12.05b

Total

N/A

130.87  7.55a

93.77  6.15b

89.47  12.13b

%
Free/Total5

N/A

0.88  0.22b

2.45  0.31b

4.68  0.90a

N/A = Not applicable due to no phytosterol treatment in diet. Values are means  SEM, n = 9-10.
1
Sum of cholesterol, dihydrocholesterol, coprostanol, and coprostanone.
2
Sum of brassicasterol, campesterol, stigmasterol, sitosterol, and sitostanol.
3
Total Sterols include both phytosterols and neutral sterols.
4
Phytosterol treatment indicates quantification of the specific treatment phytosterol only.
5
Free treatment phytosterol to total treatment phytosterol ratio is referred to as net hydrolysis.
a,b,c
Means within a row having different superscripts are statistically different (P < 0.05).
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Table 11. Bile acid excretion and fecal output
Control

Sitostanol
Stearate

Stigmasterol
Stearate

Sitosterol Stearate

µmol x day–1 × 100 g–1 body weight
Bile acids

1.38  0.06

1.41  0.08

1.53  0.06

1.29 0.09

g × day–1 × 100 g–1 body weight
Fecal Output

0.830  0.03b

0.979  0.02a

0.931  0.03a,b

0.971  0.05a

Values are means  SEM, n = 9-10.
a,b
Means within a row having different superscripts are statistically different (P < 0.05).
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Post-hoc Correlation Analysis

Esterified Neutral Sterol Fecal Excretion %
(Esterified / Total Neutral Sterol Excreition)

0.12
0.1
r = 0.63044
p = <.0001

0.08
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0
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Free Phytosterol Stearate Treatment Fecal Excretion %
(Free / Total Treatment Fecal Excretion)
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Figure 3. Post-hoc correlation analysis of esterified neutral sterol % and free phytosterol
treatment sterol % excretion(r = 0.63044, p = <0.0001). Analysis of the correlation between
esterified neutral sterol and free total phytosterol excretion demonstrated significance (r =
0.43692, p = 0.0054) as did analysis of the esterified neutral sterol and free phytosterol treatment
excretion (r = 0.65168, p = <0.0001). Because the treatments consisted of purified phytosterol
stearates, the analysis between percent esterified neutral sterol excretion and percent free
phytosterol treatment excretion was chosen for display.
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Discussion

This investigation sought to elucidate the effect of the phytosterol moiety incorporated
into phytosterol stearate esters upon the lipid-lowering efficacy of the treatment at 2.5% (g/g) of
diet. While purified phytosterol stearates and stearate-enriched phytosterol ester mixtures have
demonstrated a serum cholesterol lowering effect in both humans (Carr et al 2009) and hamsters
studies within our laboratory (Guderian Jr et al 2007, Rasmussen et al 2006), none of the
phytosterol stearate treatment groups in our current study had significantly lower plasma total,
non-HDL, or HDL cholesterol concentrations. We previously demonstrated an equivalent
significantly greater decrease in non-HDL cholesterol in hamsters fed stearic acid-enriched
phytosterol esters in comparison to soybean oil phytosterol esters (Rasmussen et al 2006).
Utilizing a 5% (g/g) dietary dose, Rasmussen et al. (2006) demonstrated superior cholesterol
lowering efficacy with increasing stearic acid enrichment in phytosterol esters indicating that the
amount of stearic acid-enrichment syngergistically results in a greater decrease of plasma
cholesterol (Rasmussen et al 2006).
While our data may have been confounded by variable food intakes during week four,
our phytosterol stearates resembled the effective purified phytostearol stearates but produced no
lowering effect upon plasma cholesterol concentrations at half the 5.0% dose administered in the
study by Rasmussen et al. (2006) indicating that possibly our treatment intake level was not
sufficient to observe the same cholesterol lowering effect by phytosterol stearates despite the
administration of ten times the 0.24% dose required to lower non-HDL cholesterol with
phytosterol canola oil esters in hamsters (Lin et al 2004, Trautwein et al 2002). Dietary treatment
with fish oil phytosterol esters at a 1.76% dose significantly lowered total cholesterol, an effect
probably due to lowered HDL cholesterol (Demonty et al 2005). A decrease in HDL cholesterol,
an effect reported by Rasmussen et al. (2006), was not even observed in the current study.
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Guderian et al. (2007) administered the same beef tallow phytosterol esters (PSE) as
Rasmussen et al. (2006) and observed a HDL cholesterol lowering effect at all doses (0.5% PSE,
1.0% PSE, and 5.0% PSE) but an effective non-HDL cholesterol lowering only with the 5.0%
dose (Guderian Jr et al 2007). Furthermore, the 0.5% PSE diet elicited the decrease in HDL
cholesterol and liver free cholesterol without the decrease in non-HDL cholesterol despite no
decrease in cholesterol absorption (Guderian Jr et al 2007). With the exception of the HDL
cholesterol lowering in the current study, we obtained remarkably similar mean cholesterol
absorption percentages to the 62.0% ± 3.3% measurement obtained for the 0.5% PSE treatment
group within the study by Guderian et al. (2007) (Guderian Jr et al 2007).
While only the 5.0% PSE dosage demonstrated an ability to lower non-HDL despite the
equivalent lowering of HDL cholesterol, a recent clinical study demonstrated that the beef tallow
phytosterol esters significantly lowered LDL cholesterol in both normo- and
hypercholesterolemic adults but did not decrease plasma HDL cholesterol concentrations (Carr et
al 2009) at when administered witin the recommended phytosterol ester intake range (Demonty
et al 2009).
An explanation for this HDL cholesterol lowering in hamsters but not humans is required,
as Bio-F1B Syrian hamsters (BioBreeders) are a strain with increased sensitivity to dietary
modifications and display high lipoprotein cholesterol distribution homology to humans
(primarily transported within VLDL and LDL) (Trautwein et al 1993). It is possible that either
the HDL cholesterol concentrations in the strain of hamster are more sensitive to dietary
modification or that phytosterol stearates are affecting cholesterol metabolism differently in
humans and hamsters, as the HDL cholesterol decrease was observed in hamsters even at the
0.5% PSE dose (Guderian Jr et al 2007).
While our investigation did not observe the HDL cholesterol lowering effect
demonstrated by Guderian et al. (2007), several design differences may explain this difference.
The current study utilized a cholesterol supplemented diet (0.12%) in Charles River outbred
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hamsters, which are more resistant to dyslipidemia than the Bio F1B hamsters fed a model Atkins
diet with 90% lean ground beef diet and no added cholesterol by Guderian et al. (2007) (Dorfman
et al 2003, Trautwein et al 1993). Because the level of dietary cholesterol has demonstrated an
ability to modulate the effects of dietary fatty acids upon the distribution of and the concentration
of lipoprotein cholesterol in hamsters (Lecker et al 2010, Mei-Huei et al 2004, Sessions and
Salter 1994), the different atherogenic diets administered in our study and the study by Guderian
et al. (2007) may be responsible for the differences observed. Regardless, there are currently no
studies demonstrating a decrease in non-HDL cholesterol with phytosterol stearates at doses
lower than 5.0% within hamsters despite the LDL cholesterol lowering effect observed in humans
at the typical dietary recommended intake (Carr et al 2009), indicating that phytosterol stearate
may act differently from other phytosterol esters depending upon the dose in hamsters (Guderian
Jr et al 2007). In another study by (Guderian Jr et al 2007), beef tallow phytosterol esters
administered at 5% PSE were more effective than a dietary treatment of 3% free phytosterols and
2% stearic acid, a treatment representing complete hydrolysis of a 5.0% dose of purified
phytosterol stearate (Guderian Jr et al 2007), suggesting that incompletely hydrolyzed phytosterol
stearates may function to lower cholesterol when given at the higher 5.0% dose.
Kobayashi et al. suggested a possible different mechanism of phytosterol stearateinduced cholesterol lowering based upon the absence of the effect at a dietary intake of 0.597% in
rats (Kobayashi et al 2008). The 0.597% dose of purified phytosterol stearate did not induce
cholesterol lowering but demonstrated a remarkable difference in the extent of net hydrolysis
between the phytosterol oleates and the phytosterol stearates as examined by the extent of free
phytosterols present in fecal matter, reporting a net hydrolysis of 99.477% for phytosterol oleate
but a dramatically reduced net hydrolysis of 19.2% for phytosterol stearate (Kobayashi et al
2008). With 2.5% (g/g) phytosterol stearates, we observed a remarkably low level of net
hydrolysis among the phytosterol stearate treatment groups in fecal matter. Furthermore, the
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percent free phytosterol stearate treatment excretion (net hydrolysis) was significantly positively
correlated to the percent excretion of esterified neutral sterol excretion (r = 0.63044, p = <
0.0001; Figure 3), indicating that the increase in neutral sterol excretion observed with the
sitosterol stearate diet may be caused by the higher level of net hydrolysis than the other
phytosterol stearate treatments that were significantly lower both in fecal esterified neutral sterol
excretion and in net hydrolysis. Specifically, the net hydrolysis was higher in the sitosterol
stearate (4.68%  0.90%) diet than the stigmasterol stearate (2.45  0.31%) and the sitosterol
stearate treatments (0.88  0.22%).
Cholesterol esterase (PCE; EC 3.1.1.13) hydrolyzes esterified sterols, including both
cholesterol and phytosterols, but the specificity of the enzyme for these different sterol and
sitostanol esters differs, conferring a net difference in extent of hydrolysis, according to in vitro
assay measurements (Brown et al 2009). Specifically, stearate esters were hydrolyzed with a 41.6
± 1.1% activity in comparison to oleate esters, supporting the findings of Kobayashi et al. (2008)
(Brown et al 2009). The in vitro assay measured the relative hydrolytic activity over 8 minutes at
37°C, a time period greatly condensed in comparison to the transit time and exposure of
phytosterol esters to cholesterol esterase (Murthy and Ganiban 1988), indicating the feasibility of
obtaining the great difference in net hydroglysis observed by Kobayashi et al. (2008) between
phytosterol oleate and stearate esters. Our net hydrolysis data closely match the cholesterol
esterase hydrolysis pattern demonstrated for specific phytosterol stearates within an in vitro
model system by Brown et al. (2009) (Brown et al 2009). Specifically, our data are in agreement
with the cholesterol esterase data in that there was no difference in the amount of net hydrolysis
between the stigmasterol stearate and sitostanol stearate treatment groups but a greater net
hydrolysis of sitosterol stearate (Brown et al 2009). Brown et al. demonstrated that cholesterol
esterase hydrolyzes stigmasterol stearate at 12.6 ± 1.6% of the rate with which it hydrolyzes
cholesterol oleate, supporting our high level of net unhydrolyzed stigmasterol stearate present in
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the fecal matter. Furthermore, the equivalency of hydrolytic rate of both palmitate and stearate
esters as demonstrated by Brown et al. (Brown et al 2009) supports the lack of difference between
beef tallow phytosterol esters and purified phytosterol stearate esters demonstrated by Rasmussen
et al. (Rasmussen et al 2006). Based upon our current data demonstrating an increased neutral
sterol excretion that appears to mirror the extent of hydrolysis data, we have formulated the
hypothesis that unhydrolyzed phytosterol stearate esters may lower cholesterol at high doses
based upon an ―oil phase‖ effect, solubilizing cholesterol within this phase and preventing
micellar incorporation.
The current understanding of phytosterol-mediated cholesterol lowering primarily
depends upon the mechanism of dietary phytosterol and cholesterol competition for
micellarization, suggesting that displacement of cholesterol from micelles by phytosterol
subsequently lowers cholesterol absorption (Jesch and Carr 2006). Work in our laboratory within
a simulated in vivo mixed-micelle system has demonstrated that phytosterol esters neither
incorporate into micelles themselves nor effect cholesterol micellar incorporation within our
model micelle conditions (Carr TP and Brown AW, unpublished data). However, whether both
of these effects hold true in vivo remains to be elucidated. The in vitro system used to model the
effect of phytosterol esters upon cholesterol micellarization did not include cholesterol esterase,
thus the possible dynamic hydrolysis and re-esterification effects of phytosterol stearates were not
included in the model of phytosterol ester impact on cholesterol absorption. Furthermore, the
absence of a phytosterol ester disruption of micellarized cholesterol supports our current data
hypothesis, suggesting that the effect may be mediated only upon reaching high levels of
phytosterol stearate intake that is inefficiently hydrolyzed by cholesterol esterase and may be
responsible for the cholesterol lowering effect observed at a 5% dose despite assumed virtual lack
of hydrolysis, an extrapolation from the data of Kobayashi et al. (2008) and the current study
(Rasmussen et al 2006). Whether this theorized oil phase is an artifact of measurement generated
upon the collection of monomeric phytosterol stearates present in the intestine or a physical
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reality, the hypothesis provides a possible explanation for why phytosterol stearates did not lower
plasma cholesterol within the current investigation at a dose of 2.5%.
In summary, sitosterol stearate elicited a slightly greater positive effect upon cholesterol
metabolism than the other phytosterol stearate esters at a 2.5% (g/g) dose by elevating esterified
neutral sterol excretion and lowering liver free cholesterol concentrations. However, this superior
effect may or may not hold for more effective doses of phytosterol stearates, as we propose that
the cholesterol lowering capacity of phytosterol stearates differs at different doses.
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